U.S. patent application number 17/396717 was filed with the patent office on 2022-06-02 for rimegepant for cgrp related disorders.
The applicant listed for this patent is Biohaven Pharmaceutical Ireland DAC. Invention is credited to Vladimir Coric, Robert Croop.
Application Number | 20220168295 17/396717 |
Document ID | / |
Family ID | 1000006140511 |
Filed Date | 2022-06-02 |
United States Patent
Application |
20220168295 |
Kind Code |
A1 |
Coric; Vladimir ; et
al. |
June 2, 2022 |
RIMEGEPANT FOR CGRP RELATED DISORDERS
Abstract
Disclosed are methods of treating CGRP related disorders, e.g.,
migraine, by administering to a patient in need thereof rimegepant
or a pharmaceutically acceptable salt thereof. Pharmaceutical
compositions comprising rimegepant and kits including the
pharmaceutical compositions and instructions are also
disclosed.
Inventors: |
Coric; Vladimir; (Madison,
CT) ; Croop; Robert; (Newton Square, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Biohaven Pharmaceutical Ireland DAC |
Dublin |
|
IE |
|
|
Family ID: |
1000006140511 |
Appl. No.: |
17/396717 |
Filed: |
August 8, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16884196 |
May 27, 2020 |
11083724 |
|
|
17396717 |
|
|
|
|
16767134 |
May 27, 2020 |
|
|
|
PCT/US2019/023940 |
Mar 25, 2019 |
|
|
|
16884196 |
|
|
|
|
62647794 |
Mar 25, 2018 |
|
|
|
62664761 |
Apr 30, 2018 |
|
|
|
62774285 |
Dec 2, 2018 |
|
|
|
62777180 |
Dec 9, 2018 |
|
|
|
62777625 |
Dec 10, 2018 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/2063 20130101;
A61K 9/2018 20130101; A61P 25/06 20180101; A61K 31/4545 20130101;
A61K 31/4709 20130101 |
International
Class: |
A61K 31/4709 20060101
A61K031/4709; A61K 9/20 20060101 A61K009/20; A61P 25/06 20060101
A61P025/06; A61K 31/4545 20060101 A61K031/4545 |
Claims
1-21. (canceled)
22. A pharmaceutical composition comprising a pharmaceutically
acceptable carrier and a therapeutically effective amount of
rimegepant, or a pharmaceutically acceptable salt thereof, wherein
the pharmaceutical composition is in a form of an oral solid molded
fast-dispersing dosage form.
23. The pharmaceutical composition of claim 22, wherein the
rimegepant is in the form of a hemisulfate salt.
24. The pharmaceutical composition of claim 22, wherein the
rimegepant is in the form of a hemisulfate sesquihydrate salt.
25. The pharmaceutical composition of claim 22, further comprising
gelatin as a carrier.
26. The pharmaceutical composition of claim 22, further comprising
mannitol as a filler.
27. The pharmaceutical composition of claim 22, comprising from
about 70-80 weight % of the rimegepant or a pharmaceutically
acceptable salt thereof, about 10-20 weight % fish gelatin, about
10-20 weight % of a filler, and 0.1-5.0 weight % of a
flavorant.
28. The pharmaceutical composition of claim 22, wherein the
pharmaceutical composition is capable of disintegrating or
dispersing within an interval selected from 1 to 60 seconds, 1 to
30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed
in contact with a fluid.
29. The pharmaceutical composition of claim 28, wherein the fluid
comprises saliva.
30. The pharmaceutical composition of claim 22 in the form of a
tablet.
31. The pharmaceutical composition of claim 22, that provides an
AUC.sub.0-t of from about 80-125% of 5000 (hr*ng/mL).
32. A method of treating migraine in a patient in need thereof,
comprising administering to the patient a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of rimegepant, or a
pharmaceutically acceptable salt thereof, wherein the
pharmaceutical composition is in a form of an oral solid molded
fast-dispersing dosage form.
33. The method of claim 32, wherein the rimegepant is in the form
of a hemisulfate salt.
34. The method of claim 32, wherein the rimegepant is in the form
of a hemisulfate sesquihydrate salt.
35. The method of claim 32, wherein the pharmaceutical composition
further comprises gelatin as a carrier.
36. The method of claim 32, wherein the pharmaceutical composition
further comprises mannitol as a filler.
37. The method of claim 32, wherein the pharmaceutical composition
comprises from about 70-80 weight % of the rimegepant or a
pharmaceutically acceptable salt thereof, about 10-20 weight % fish
gelatin, about 10-20 weight % of a filler, and 0.1-5.0 weight % of
a flavorant.
38. The method of claim 32, wherein the pharmaceutical composition
is capable of disintegrating or dispersing within an interval
selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds,
and 2 to 8 seconds, after being placed in contact with a fluid.
39. The method of claim 38, wherein the fluid comprises saliva.
40. The method of claim 32, wherein the pharmaceutical composition
is in the form of a tablet.
41. The method of claim 32, wherein the pharmaceutical composition
provides an AUC.sub.0-t of from about 80-125% of 5000 (hr*ng/mL).
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 16/767,134 filed May 27, 2020, which is a national stage
application under 35 U.S.C. .sctn. 371 of International Application
No. PCT/US2019/023940, filed Mar. 25, 2019, which claims priority
to U.S. Provisional Application No. 62/647,794 filed Mar. 25, 2018,
U.S. Provisional Application No. 62/664,761 filed Apr. 30, 2018,
U.S. Provisional Application No. 62/774,285 filed Dec. 2, 2018,
U.S. Provisional Application No. 62/777,180 filed Dec. 9, 2018, and
U.S. Provisional Application No. 62/777,625 filed Dec. 10, 2018,
and all the benefits accruing therefrom under 35 U.S.C. .sctn. 119,
the disclosure of each of which applications is herein incorporated
by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to the use of rimegepant and
salts thereof for treating CGRP-related disorders such as
migraine.
BACKGROUND OF THE INVENTION
[0003] Migraine is a chronic and debilitating disorder
characterized by recurrent attacks lasting four to 72 hours with
multiple symptoms, including typically one-sided, pulsating
headaches of moderate to severe pain intensity that are associated
with nausea or vomiting, and/or sensitivity to sound (phonophobia)
and sensitivity to light (photophobia). Migraines are often
preceded by transient neurological warning symptoms, known as
auras, which typically involve visual disturbances such as flashing
lights, but may also involve numbness or tingling in parts of the
body. Migraine is both widespread and disabling. The Migraine
Research Foundation ranks migraine as the world's third most
prevalent illness, and the Global Burden of Disease Study 2015
rates migraine as the seventh highest specific cause of disability
worldwide. According to the Migraine Research Foundation, in the
United States, approximately 36 million individuals suffer from
migraine attacks. While most sufferers experience migraine attacks
once or twice per month, more than 4 million people have chronic
migraine, defined as experiencing at least 15 headache days per
month, of which at least eight are migraine, for more than three
months. Others have episodic migraine, which is characterized by
experiencing less than 15 migraine days per month. People with
episodic migraine may progress to chronic migraine over time.
Migraine attacks can last four hours or up to three days. More than
90% of individuals suffering from migraine attacks are unable to
work or function normally during a migraine attack, with many
experiencing comorbid conditions such as depression, anxiety and
insomnia. Also, those suffering from migraine often have
accompanying nausea and have an aversion to consuming food or
liquids during an attack.
[0004] CGRP (calcitonin gene-related peptide) is a 37 amino acid
neuropeptide, which belongs to a family of peptides that includes
calcitonin, adrenomedullin and amylin. In humans, two forms of CGRP
(a-CGRP and 13-CGRP) exist and have similar activities. They vary
by three amino acids and exhibit differential distribution. At
least two CGRP receptor subtypes may also account for differential
activities. The CGRP receptor is located within pain-signaling
pathways, intracranial arteries and mast cells and its activation
is thought to play a causal role in migraine pathophysiology. For
example, research and clinical studies have shown: serum levels of
CGRP are elevated during migraine attacks, infusion of intravenous
CGRP produces persistent pain in migraine sufferers and
non-migraine sufferers, and treatment with anti-migraine drugs
normalizes CGRP activity.
[0005] Possible CGRP involvement in migraine has been the basis for
the development and clinical testing of a number of compounds,
including for example, olcegepant (Boehringer Ingelheim,
Ridgefield, Conn.), telcagepant (Merck Sharp & Dohme Corp.,
Kenilworth, N.J.), ubrogepant (Allergan plc, Dublin, Ireland),
rimegepant (Biohaven Pharmaceutical Holding Company Ltd., New
Haven, Conn.), galcanezumab (Eli Lilly and Company, Indianapolis,
Ind.), fremanezumab (Teva Pharmaceutical Industries, Petah Tikva,
Israel), eptinezumab (Alder Biopharmaceuticals, Inc., Bothell,
Wash.), and erenumab (Amgen Inc., Thousand Oaks, Calif.). Another
compound recently studies for treatment of migraine is lasmiditan
(Eli Lilly and Company, Indianapolis, Ind.).
[0006] Currently, clinicians use a number of pharmacologic agents
for the acute treatment of migraine. A study published by the
American Headache Society in 2015 concluded that the medications
deemed effective for the acute treatment of migraine fell into the
following classes: triptans, ergotamine derivatives, non-steroidal
anti-inflammatory drugs ("NSAIDs"), opioids and combination
medications. The current standard of care for the acute treatment
of migraine is prescription of triptans, which are serotonin
5-HT.sub.1B/1D receptor agonists. Triptans have been developed and
approved for the acute treatment of migraine over the past two
decades. The initial introduction of triptans represented a shift
toward drugs more selectively targeting the suspected
pathophysiology of migraine. While triptans account for almost 80%
of anti-migraine therapies prescribed at office visits by
healthcare providers, issues such as an incomplete effect or
headache recurrence remain important clinical limitations. In fact,
only about 30% of patients from clinical trials are pain free at
two hours after taking triptans. In addition, triptans are
contraindicated in patients with cardiovascular disease,
cerebrovascular disease, or significant risk factors for either
because of potential systemic and cerebrovascular vasoconstriction
from the 5-HT.sub.1B-mediated effects. Also, according to a January
2017 study published in the journal Headache, an estimated 2.6
million migraine sufferers in the United States have a
cardiovascular event, condition or procedure that limits the
potential of triptans as a treatment option.
[0007] Accordingly, there remains a significant unmet medical need
for the treatment of migraine that may provide enhanced patient
benefits compared to existing therapies. In addition, CGRP receptor
antagonists may be useful pharmacological agents for disorders that
involve other CGRP disorders. In addition to migraine, such
disorders may include cluster headache (Doods (2001) Curr. Opin.
Invest. Drugs 2, 1261-1268; Edvinsson et al. (1994) Cephalalgia 14,
320-327); chronic tension type headache (Ashina et al. (2000)
Neurology 14, 1335-1340); pain (Yu et al. (1998) Eur. J Pharmacol.
347, 275-282); chronic pain (Hulsebosch et al. (2000) Pain 86,
163-175); neurogenic inflammation and inflammatory pain (Holzer
(1988) Neuroscience 24, 739-768; Delay-Goyet et al. (1992) Acta
Physiol. Scanda. 146, 537-538; Salmon et al. (2001) Nature
Neurosci. 4, 357-358); eye pain (May et al. (2002) Cephalalgia 22,
195-196), tooth pain (Awawdeh et al. (2002) Int. Endocrin. 135,
30-36), non-insulin dependent diabetes mellitus (Molina et al.
(1990) Diabetes 39, 260-265); vascular disorders; inflammation
(Zhang et al. (2001) Pain 89,265); arthritis, bronchial
hyperreactivity, asthma, (Foster et al. (1992) Ann. NY Acad. Sci.
657, 397-404; Schini et al. (1994) Am. J Physiol. 267, H2483-H2490;
Zheng et al. (1993) J Viral. 67, 5786-5791); shock, sepsis (Beer et
al. (2002) Crit. Care Med. 30, 1794-1798); opiate withdrawal
syndrome (Salmon et al. (2001) Nature Neurosci. 4, 357-358);
morphine tolerance (Menard et al. (1996) J Neurosci. 16,
2342-2351); hot flashes in men and women (Chen et al. (1993) Lancet
342, 49; Spetz et al. (2001) J Urology 166, 1720-1723); allergic
dermatitis (Wallengren (2000) Contact Dermatitis 43, 137-143);
psoriasis; encephalitis, brain trauma, ischaemia, stroke, epilepsy,
and neurodegenerative diseases (Rohrenbeck et al. (1999) Neurobiol.
Dis. 6, 15-34); skin diseases (Geppetti and Holzer, Eds.,
Neurogenic Inflammation, 1996, CRC Press, Boca Raton, Fla.),
neurogenic cutaneous redness, skin rosaceousness and erythema;
tinnitus (Herzog et al. (2002) J Membr. Biol. 189,225); obesity
(Walker et al. (2010) Endocrinology 151, 4257-4269); inflammatory
bowel disease, irritable bowel syndrome, (Hoffman et al. (2002)
Scand. J Gastroenterol. 37, 414-422) and cystitis.
SUMMARY OF THE INVENTION
[0008] The present invention is directed, among other things, to
the treatment of CGRP related disorders, e.g., migraine, with
rimegepant and salts thereof. By virtue of the present invention,
it may now be possible to provide more effective GCRP related
treatments to patients. Patients suffering from migraine may
experience an improved response in one or more areas including, for
example, fewer migraine headaches, improvements in pain freedom or
freedom from most bothersome symptoms.
[0009] In one aspect of the invention, there is provided a method
of treating migraine in a patient in need thereof, comprising
administering to the patient a pharmaceutical composition
comprising a therapeutically effective amount of rimegepant, or a
pharmaceutically acceptable salt thereof, in order to provide
decrease in the number of migraines per month for said patient of
at least 20%.
[0010] In one aspect of the invention, the decrease in the number
of migraines per month for said patient of at least 30%. In one
aspect of the invention, the decrease in the number of migraines
per month for said patient of at least 40%.
[0011] In one aspect of the invention, there is provided a method
of treating migraine in a patient in need thereof, comprising
administering to the patient a pharmaceutical composition
comprising a therapeutically effective amount of rimegepant, or a
pharmaceutically acceptable salt thereof, in order to provide Pain
Freedom of the pharmaceutical composition of at about 30% greater
than placebo.
[0012] In one aspect of the invention, the Pain Freedom is at least
about 50% greater than placebo. In one aspect of the invention, the
Pain Freedom of the pharmaceutical composition is from about 30-75%
greater than placebo. In one aspect of the invention, the Pain
Freedom is from about 35-65% greater than placebo.
[0013] In one aspect of the invention, there is provided a method
of treating migraine in a patient in need thereof, comprising
administering to the patient a pharmaceutical composition
comprising a therapeutically effective amount of rimegepant, or a
pharmaceutically acceptable salt thereof, in order to provide
Freedom from MBS of the pharmaceutical composition of at about 30%
greater than placebo.
[0014] In one aspect of the invention, the Freedom from MBS is at
least about 40% greater than placebo. In one aspect of the
invention, the Freedom from MBS is from about 30-50% greater than
placebo. In one aspect of the invention, the Freedom from MBS is
from about 35-65% greater than placebo.
[0015] In one aspect of the invention, the method provides an
AUC.sub.0-t of from about 80-125% of 5000 (hr*ng/mL). In one aspect
of the invention, the method provides an AUC.sub.0-t of from about
85-115% of 5000 (hr*ng/mL). In one aspect of the invention, the
method provides an AUC.sub.0-t of from about 90-105% of 5000
(hr*ng/mL).
[0016] In one aspect of the invention, the method provides a
C.sub.max of from about 80-125% of 835 (ng/mL). In one aspect of
the invention, the method provides a C.sub.max of from about
85-120% of 835 (ng/mL). In one aspect of the invention, the method
provides a C.sub.max of from about 95-115% of 835 (ng/mL).
[0017] In one aspect of the invention, the pharmaceutical
composition is administered by oral, sublingual or buccal
administration.
[0018] In one aspect of the invention, the pharmaceutical
composition comprises from about 10 to 600 mg of rimegepant or a
pharmaceutically acceptable salt thereof. In one aspect of the
invention, the pharmaceutical composition comprises from about 25
to 300 mg of rimegepant or a pharmaceutically acceptable salt
thereof. In one aspect of the invention, the pharmaceutical
composition comprises from about 25 to 150 mg of rimegepant or a
pharmaceutically acceptable salt thereof. In one aspect of the
invention, the pharmaceutical composition comprises from about 50
to 100 mg of rimegepant or a pharmaceutically acceptable salt
thereof. In one aspect of the invention, the pharmaceutical
composition comprises from about 70 to 80 mg of rimegepant or a
pharmaceutically acceptable salt thereof. In one aspect of the
invention, the pharmaceutical composition comprises about 75 mg of
rimegepant or a pharmaceutically acceptable salt thereof. In one
aspect of the invention, the pharmaceutical composition comprises
about 150 mg of rimegepant or a pharmaceutically acceptable salt
thereof. In one aspect of the invention, the pharmaceutical
composition comprises about 37.5 mg of rimegepant or a
pharmaceutically acceptable salt thereof.
[0019] In one aspect of the invention, the rimegepant is in the
form of a hemisulfate sesquihydrate salt.
[0020] In one aspect of the invention, there is provided a
pharmaceutical composition comprising a therapeutically effective
amount of rimegepant, or a pharmaceutically acceptable salt
thereof, in order to provide an AUC.sub.0-t of from about 80-125%
of 5000 (hr*ng/mL).
[0021] In one aspect of the invention, there is provided a
pharmaceutical composition comprising a therapeutically effective
amount of rimegepant, or a pharmaceutically acceptable salt
thereof, in order to provide a C.sub.max of from about 80-125% of
835 (ng/mL).
[0022] In one aspect of the invention, the pharmaceutical
composition is provided in the form of a tablet. In one aspect of
the invention, the pharmaceutical composition comprises from about
50-60 wt % rimegepant hemisulfate sesquihydrate, about 30-35 wt %
microcrystalline cellulose, about 2-7 wt % hydroxypropyl cellulose,
about 3-7 wt % croscarmellose sodium, and about 0.1-1.0 wt %
magnesium stearate. In one aspect of the invention, the
pharmaceutical composition comprises about 57.1 wt % rimegepant
hemisulfate sesquihydrate, about 33.4 wt % microcrystalline
cellulose, about 4.0 wt % hydroxypropyl cellulose, about 5.0 wt %
croscarmellose sodium, and about 0.5 wt % magnesium stearate.
[0023] In one aspect of the invention, the pharmaceutical
composition is provided in the form of an oral solid molded
fast-dispersing dosage form. In one aspect of the invention, the
pharmaceutical composition comprises from about 70-80 wt %
rimegepant hemisulfate sesquihydrate, about 10-20 wt % fish
gelatin, about 10-20 wt % of a filler, and 0.1-5.0 wt % of a
flavorant. In one aspect of the invention, the filler is
mannitol.
[0024] In one aspect of the invention, there is provided a method
of treating a condition associated with aberrant levels of CGRP in
a patient in need thereof, comprising administering to the patient
a pharmaceutical composition comprising a therapeutically effective
amount of rimegepant, or a pharmaceutically acceptable salt
thereof, in order to provide an AUC.sub.0-t of from about 80-125%
of 5000 (hr*ng/mL).
[0025] In one aspect of the invention, there is provided a method
of treating a condition associated with aberrant levels of CGRP in
a patient in need thereof, comprising administering to the patient
a pharmaceutical composition comprising a therapeutically effective
amount of rimegepant, or a pharmaceutically acceptable salt
thereof, in order to provide a C.sub.max of from about 80-125% of
835 (ng/mL). In one aspect of the invention, the disorder is
selected from: migraine and cluster headache; chronic tension type
headache; chronic pain; neurogenic inflammation and inflammatory
pain; eye pain; tooth pain; non-insulin dependent diabetes
mellitus; vascular disorders; inflammation; arthritis; bronchial
hyperreactivity; asthma; shock; sepsis; opiate withdrawal syndrome;
morphine tolerance; hot flashes in men and women; allergic
dermatitis; psoriasis; encephalitis, brain trauma, ischaemia,
stroke, epilepsy, and neurodegenerative diseases; skin diseases;
neurogenic cutaneous redness, skin rosaceousness and erythema;
tinnitus; obesity; inflammatory bowel disease; irritable bowel
syndrome; and cystitis.
[0026] In one aspect of the invention, there is provided a kit for
treating a condition associated with aberrant levels of CGRP in a
patient, the kit comprising:
[0027] (a) a pharmaceutical composition comprising a
therapeutically effective amount of rimegepant, or a
pharmaceutically acceptable salt thereof;
[0028] (b) instructions for administering the pharmaceutical
composition;
[0029] wherein the therapeutically effective amount provides an
AUC.sub.0-t of from about 80-125% of 5000 (hr*ng/mL).
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG. 1 shows the probability of pain freedom versus time in
a clinical study entitled BHV3000-301: Phase 3: Double-Blind,
Randomized, Placebo-Controlled, Safety and Efficacy Trial of
BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
(ClinicalTrials.gov Identifier: NCT03235479).
[0031] FIG. 2 shows the probability of pain freedom versus time in
a clinical study entitled BHV3000-302: Phase 3: Double-Blind,
Randomized, Placebo-Controlled, Safety and Efficacy Trial of
BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
(ClinicalTrials.gov Identifier: NCT03237845).
[0032] FIG. 3 shows the time to pain relief up to 8 hours pose dose
in a clinical study entitled BHV3000-301: Phase 3: Double-Blind,
Randomized, Placebo-Controlled, Safety and Efficacy Trial of
BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
(ClinicalTrials.gov Identifier: NCT03235479).
[0033] FIG. 4 shows the time to pain relief up to 8 hours pose dose
in a clinical study entitled BHV3000-302: Phase 3: Double-Blind,
Randomized, Placebo-Controlled, Safety and Efficacy Trial of
BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
(ClinicalTrials.gov Identifier: NCT03237845).
[0034] FIG. 5 shows a Kaplan-Meier pain relief curve through 2
hours after a single dose of rimegepant 75 mg Zydis ODT in a
clinical study entitled BHV3000-303: Phase 3: Double-Blind,
Randomized, Placebo-Controlled, Safety and Efficacy Trial of
BHV-3000 (Rimegepant) Orally Discintegrating Tablet (ODT) for the
Acute Treatment of Migraine (ClinicalTrials.gov Identifier:
NCT03461757).
[0035] FIG. 6 shows a pain free freedom from 2 to 8 hours after a
single dose of rimegepant 75 mg Zydis ODT in a clinical study
entitled BHV3000-303: Phase 3: Double-Blind, Randomized,
Placebo-Controlled, Safety and Efficacy Trial of BHV-3000
(Rimegepant) Orally Discintegrating Tablet (ODT) for the Acute
Treatment of Migraine (ClinicalTrials.gov Identifier:
NCT03461757).
DETAILED DESCRIPTION OF THE INVENTION
[0036] The following detailed description is provided to aid those
skilled in the art in practicing the present invention. Those of
ordinary skill in the art may make modifications and variations in
the embodiments described herein without departing from the spirit
or scope of the present disclosure. Unless otherwise defined, all
technical and scientific terms used herein have the same meaning as
commonly understood by one of ordinary skill in the art to which
this disclosure belongs. The terminology used in the description is
for describing particular embodiments only and is not intended to
be limiting.
[0037] As used in this application, except as otherwise expressly
provided herein, each of the following terms shall have the meaning
set forth below. Additional definitions are set forth throughout
the application. In instances where a term is not specifically
defined herein, that term is given an art-recognized meaning by
those of ordinary skill applying that term in context to its use in
describing the present invention.
[0038] The articles "a" and "an" refer to one or to more than one
(i.e., to at least one) of the grammatical object of the article
unless the context clearly indicates otherwise. By way of example,
"an element" means one element or more than one element.
[0039] The term "about" refers to a value or composition that is
within an acceptable error range for the particular value or
composition as determined by one of ordinary skill in the art,
which will depend in part on how the value or composition is
measured or determined, i.e., the limitations of the measurement
system. For example, "about" can mean within 1 or more than 1
standard deviation per the practice in the art. Alternatively,
"about" can mean a range of up to 1%, 5%, 10% or 20% (i.e., .+-.10%
or .+-.20%) depending on the context of the application. For
example, about 3 mg can include any number between 2.7 mg and 3.3
mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%). Furthermore,
particularly with respect to biological systems or processes, the
terms can mean up to an order of magnitude or up to 5-fold of a
value. When particular values or compositions are provided in the
application and claims, unless otherwise stated, the meaning of
"about" should be assumed to be within an acceptable error range
for that particular value or composition.
[0040] The term "administering" refers to the physical introduction
of a composition comprising a therapeutic agent to a subject, using
any of the various methods and delivery systems known to those
skilled in the art. Administering can also be performed, for
example, once, a plurality of times, and/or over one or more
extended periods and can be a therapeutically effective dose or a
subtherapeutic dose.
[0041] The term "AUC" (area under the curve) refers to a total
amount of drug absorbed or exposed to a subject. Generally, AUC may
be obtained from mathematical method in a plot of drug
concentration in the subject over time until the concentration is
negligible. The term "AUC" could also refer to partial AUC at
specified time intervals.
[0042] The term "Cmax" refers to a maximum concentration of a drug
in blood, serum, a specified compartment or test area of a subject
between administration of a first dose and administration of a
second dose. The term Cmax could also refer to dose normalized
ratios, if specified.
[0043] The term "dosing interval," refers to the amount of time
that elapses between multiple doses of a formulation disclosed
herein being administered to a subject. Dosing interval can thus be
indicated as ranges.
[0044] The term "dosing frequency" refers to the frequency of
administering doses of a formulation disclosed herein in a given
time. Dosing frequency can be indicated as the number of doses per
a given time, e.g., once a week or once in two weeks.
[0045] The terms "in combination with" and "in conjunction with"
refer to administration of one treatment modality in addition to
another treatment modality. As such, "in combination with" or "in
conjunction with" refers to administration of one treatment
modality before, during, or after administration of the other
treatment modality to the subject.
[0046] The term "pharmaceutically acceptable salt" refers to a salt
form of one or more of the compounds described herein which are
typically presented to increase the solubility of the compound in
the gastric or gastroenteric juices of the patient's
gastrointestinal tract in order to promote dissolution and the
bioavailability of the compounds. Pharmaceutically acceptable salts
include those derived from pharmaceutically acceptable inorganic or
organic bases and acids, where applicable. Suitable salts include,
for example, those derived from alkali metals such as potassium and
sodium, alkaline earth metals such as calcium, magnesium and
ammonium salts, among numerous other acids and bases well known in
the pharmaceutical art.
[0047] The terms "subject" and "patient" refer any human or
nonhuman animal. The term "nonhuman animal" includes, but is not
limited to, vertebrates such as nonhuman primates, sheep, dogs, and
rodents such as mice, rats and guinea pigs. In some embodiments,
the subject is a human. The terms, "subject" and "patient" are used
interchangeably herein.
[0048] The terms "effective amount", "therapeutically effective
amount", "therapeutically effective dosage" and "therapeutically
effective dose" of an agent (also sometimes referred to herein as a
"drug") refers to any amount of the agent that, when used alone or
in combination with another agent, protects a subject against the
onset of a disease or promotes disease regression evidenced by a
decrease in severity of disease symptoms, an increase in frequency
and duration of disease symptom-free periods, or relief from
impairment or disability due to the disease affliction. The
therapeutically effective amount of an agent can be evaluated using
a variety of methods known to the skilled practitioner, such as in
human subjects during clinical trials, in animal model systems
predictive of efficacy in humans, or by assaying the activity of
the agent in in vitro assays.
[0049] The term "T.sub.max" refers to a time or period after
administration of a drug when the maximum concentration (Cmax) is
reached in blood, serum, a specified compartment or test area of a
subject.
[0050] The term "treatment" refers to any treatment of a condition
or disease in a subject and may include: (i) preventing the disease
or condition from occurring in the subject which may be predisposed
to the disease but has not yet been diagnosed as having it; (ii)
inhibiting the disease or condition, i.e., arresting its
development; relieving the disease or condition, i.e., causing
regression of the condition; or (iii) ameliorating or relieving the
conditions caused by the disease, i.e., symptoms of the disease.
Treatment could be used in combination with other standard
therapies or alone. Treatment or "therapy" of a subject also
includes any type of intervention or process performed on, or the
administration of an agent to, the subject with the objective of
reversing, alleviating, ameliorating, inhibiting, slowing down or
preventing the onset, progression, development, severity or
recurrence of a symptom, complication or condition, or biochemical
indicia associated with a disease.
[0051] With respect to headache, "treatment" is an approach for
obtaining beneficial or desired results with a subject. For
purposes of this invention, beneficial or desired clinical results
include, but are not limited to, one or more of the following:
improvement in any aspect of a headache including lessening
severity, alleviation of pain intensity, and other associated
symptoms, reducing frequency of recurrence, increasing the quality
of life of those suffering from the headache, decreasing dose of
other medications required to treat the headache and reducing the
number of headache days per month. For migraine, other associated
symptoms include, but are not limited to, nausea, vomiting, and
sensitivity to light, sound, and/or movement. For cluster headache,
other associated symptoms include, but are not limited to swelling
under or around the eyes, excessive tears, red eye, Rhinorrhea or
nasal congestion, and red flushed face.
[0052] For purposes of this disclosure, reference is made to the
publication by the U.S. Food and Drug Administration (FDA),
Guidance for Industry, "Migraine: Developing Drugs for Acute
Treatment", February 2018, available from
www.fda.gov/downloads/drugs/guidances/ucm419465.pdf. Terms used in
the Examples, such as, for example, most bothersome symptoms (MBS)
and Pain Freedom, are described in the FDA Guidance.
[0053] The starting materials useful for making the pharmaceutical
compositions of the present invention are readily commercially
available or can be prepared by those skilled in the art.
[0054] Rimegepant has the chemical formula,
C.sub.28H.sub.28F.sub.2N.sub.6O.sub.3 and the IUPAC name
[(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohep-
ta[b]pyridin-9-yl]
4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate.
Rimegepant is also referred to herein as BHV-3000.
[0055] The structure of rimegepant is:
##STR00001##
[0056] Rimegepant is described, for example in WO 2011/046997
published Apr. 21, 2011.
[0057] In a preferred aspect of the invention, rimegepant is
present in the form of a hemisulfate sesquihydrate salt. This
preferred salt form is described in WO 2013/130402 published Sep.
6, 2013.
[0058] The chemical formula of the salt form is
C.sub.28H.sub.28F.sub.2N.sub.6O.sub.3.0.5H.sub.2SO.sub.4.1.5H.sub.2O
and the structure is as follows:
##STR00002##
[0059] The pharmaceutical compositions of the present invention can
be prepared in any suitable dosage form including, for example,
such as tablets, capsules, nasal sprays, powders, granules,
ointments, solutions, suppositories, injections, inhalants, gels,
microspheres, and aerosols.
[0060] The pharmaceutical compositions of the present invention
comprising rimegepant typically also include other pharmaceutically
acceptable carriers (also referred to as excipients) such as, for
example, binders, lubricants, diluents, coatings, disintegrants,
barrier layer components, glidants, coloring agents, solubility
enhancers, gelling agents, fillers, proteins, co-factors,
emulsifiers, solubilizing agents, suspending agents, flavorants,
preservatives and mixtures thereof. The choice of excipients
depends on the desired characteristics of the compositions and on
the nature of other pharmacologically active compounds in the
formulation. Suitable excipients are known to those skilled in the
art (see Handbook of Pharmaceutical Excipients, fifth edition, 2005
edited by Rowe et al., McGraw Hill).
[0061] Examples of pharmaceutically acceptable carriers that may be
used in preparing the pharmaceutical compositions of the present
invention may include, but are not limited to, fillers such as
sugars, including lactose, sucrose, mannitol, or sorbitol;
cellulose preparations such as maize starch, wheat starch, rice
starch, potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropyl methyl-cellulose, sodium carboxymethylcellulose,
polyvinyl-pyrrolidone (PVP), talc, calcium sulphate, vegetable
oils, synthetic oils, polyols, alginic acid, phosphate buffered
solutions, emulsifiers, isotonic saline, pyrogen-free water and
combinations thereof.. If desired, disintegrating agents may be
combined as well, and exemplary disintegrating agents may be, but
not limited to, cross-linked polyvinyl pyrrolidone, agar, or
alginic acid or a salt thereof such as sodium alginate. In an
aspect of the invention, the flavoring agent is selected from mint,
peppermint, berries, cherries, menthol and sodium chloride
flavoring agents, and combinations thereof. In an aspect of the
invention, the sweetener is selected from sugar, sucralose,
aspartame, acesulfame, neotame, and combinations thereof.
[0062] In general, the pharmaceutical compositions of the present
invention may be manufactured in conventional methods known in the
art, for example, by means of conventional mixing, dissolving,
granulating, dragee-making, levigating, emulsifying, encapsulating,
entrapping, lyophilizing processes and the like.
[0063] In one aspect of the invention the pharmaceutical
compositions are prepared in oral solid molded fast-dispersing
dosage form, such as described in U.S. Pat. No. 9,192,580, issued
Nov. 24, 2015.
[0064] The phrase "fast-dispersing dosage form" refers to
compositions which disintegrate or disperse within 1 to 60 seconds,
preferably 1 to 30 seconds, more preferably 1 to 10 seconds and
particularly 2 to 8 seconds, after being placed in contact with a
fluid. The fluid is preferably that found in the oral cavity, i.e.,
saliva, as with oral administration.
[0065] In a preferred embodiment, the compositions of the invention
are solid fast-dispersing dosage forms comprising a solid network
of the active ingredient, rimegepant, and a water-soluble or
water-dispersible carrier containing fish gelatin. Accordingly, the
carrier is inert towards the active ingredient. The network is
obtained by subliming solvent from a composition in the solid
state, the composition comprising the active ingredient and a
solution of the carrier in the solvent. The dosage forms according
to the invention can be prepared according to the process disclosed
in Gregory et al., U.K. Patent No. 1,548,022 using fish gelatin as
the carrier. Accordingly, an initial composition (or admixture)
comprising the active ingredient and a solution of the fish gelatin
carrier in a solvent is prepared followed by sublimation. The
sublimation is preferably carried out by freeze drying the
composition. The composition can be contained in a mold during the
freeze-drying process to produce a solid form in any desired shape.
The mold can be cooled using liquid nitrogen or solid carbon
dioxide in a preliminary step prior to the deposition of the
composition therein. After freezing the mold and composition, they
are next subjected to reduced pressure and, if desired, controlled
application of heat to aid in sublimation of solvent. The reduced
pressure applied in the process can be below about 4 mm Hg,
preferably below about 0.3 mm Hg. The freeze dried compositions can
then be removed from the mold if desired or stored therein until
later use.
[0066] When the process is used with active ingredients and fish
gelatin as the carrier, a solid fast-dispersing dosage form is
produced having the advantages associated with the use of fish
gelatin described herein. Generally, fish gelatin is categorized as
being from cold water and warm water fish sources and as being of
the gelling or non-gelling variety. The non-gelling variety of fish
gelatin, in comparison to gelling fish gelatin and bovine gelatin,
contains lower proline and hydroxyproline amino acid content, which
are known to be associated with cross-linking properties and
gelling ability. Non-gelling fish gelatin can remain at solution
concentrations of up to about 40% as well as in temperatures as low
as 20.degree. C. In one aspect of the invention, the fish gelatin
used in accordance with the invention is preferably obtained from
cold water fish sources and is the non-gelling type of fish
gelatin. More preferably, in one aspect of the invention, the
non-hydrolyzed form of non-gelling fish gelatin is used. In an
alternative embodiment, spray-dried non-hydrolyzed non-gelling fish
gelatin can be used. Fish gelatins suitable for use in the
invention are commercially available.
[0067] The compositions according to the invention can also
contain, in addition to the active ingredient arid fish gelatin
carrier, other matrix forming agents and secondary components.
Matrix forming agents suitable for use in the present invention
include materials derived from animal or vegetable proteins, such
as other gelatins, dextrins and soy, wheat and psyllium seed
proteins; gums such as acacia, guar, agar, and xanthan;
polysaccharides; alginates; carboxymethylcelluloses; carrageenans;
dextrans; pectins; synthetic polymers such as polyvinylpyrrolidone;
and polypeptide/protein or polysaccharide complexes such as
gelatin-acacia complexes.
[0068] Other materials which may also be incorporated into the
fast-dissolving compositions of the present invention include
sugars such as mannitol, dextrose, lactose, galactose, and
trehalose; cyclic sugars such as cyclodextrin; inorganic salts such
as sodium phosphate, sodium chloride and aluminum silicates; and
amino acids having from 2 to 12 carbon atoms such as glycine,
L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline,
L-isoleucine, L-leucine and L-phenylalanine. One or more matrix
forming agents may be incorporated into the solution or suspension
prior to solidification (freezing). The matrix forming agent may be
present in addition to a surfactant or to the exclusion of a
surfactant. In addition to forming the matrix, the matrix forming
agent may aid in maintaining the dispersion of any active
ingredient within the solution of suspension. This is especially
helpful in the case of active agents that are not sufficiently
soluble in water and must, therefore, be suspended rather than
dissolved. Secondary components such as preservatives,
antioxidants, surfactants, viscosity enhancers, coloring agents,
flavoring agents, pH modifiers, sweeteners or taste-masking agents
may also be incorporated into the fast-dissolving compositions.
Suitable coloring agents include red, black and yellow iron oxides
and FD & C dyes such as FD&C Blue No. 2 and FD&C Red
No. 40 available from Ellis & Everard. Suitable flavoring
agents include mint, raspberry, licorice, orange, lemon,
grapefruit, caramel, vanilla, cherry and grape flavors and
combinations of these. Suitable pH modifiers include the edible
acids and bases, such as citric acid, tartaric acid, phosphoric
acid, hydrochloric acid, maleic acid and sodium hydroxide. Suitable
sweeteners include, for example, sucralose, aspartame, acesulfame K
and thaumatin. Suitable taste-masking agents include, for example,
sodium bicarbonate, ion exchange resins, cyclodextrin inclusion
compounds, adsorbates or microencapsulated actives.
[0069] Typical routes of administering the pharmaceutical
compositions of the invention include, without limitation, oral,
topical, transdermal, inhalation, parenteral, sublingual, buccal,
rectal, vaginal, and intranasal. The term parenteral as used herein
includes subcutaneous injections, intravenous, intramuscular,
intrasternal injection or infusion techniques. Pharmaceutical
compositions according to certain embodiments of the present
invention are formulated so as to allow the active ingredients
contained therein to be bioavailable upon administration of the
composition to a patient. Compositions that will be administered to
a subject or patient may take the form of one or more dosage units.
Actual methods of preparing such dosage forms are known, or will be
apparent, to those skilled in this art; for example, see Remington:
The Science and Practice of Pharmacy, 20th Edition (Philadelphia
College of Pharmacy and Science, 2000).
[0070] Solid compositions are normally formulated in dosage units
providing from about 1 to about 1000 mg of the active ingredient
per dose. Some examples of solid dosage units are 0.1 mg, 1 mg, 10
mg, 37.5 mg, 75 mg, 100 mg, 150 mg, 300 mg, 500 mg, 600 mg and 1000
mg. Typical dose ranges in accordance with the present invention
include from about 10-600 mg, 25-300 mg, 25-150 mg, 50-100 mg,
60-90 mg, and 70-80 mg. Liquid compositions are generally in a unit
dosage range of 1-100 mg/mL. Some examples of liquid dosage units
are 0.1 mg/mL, 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100
mg/mL.
[0071] In some embodiments, a method may comprise administering to
a subject one or more additional agent(s) simultaneously or
sequentially with the rimegepant. In some embodiments, an
additional agent may be an anti-headache medication such as an
example anti-headache medication (e.g., 5-HT1 agonists, triptans,
ergot alkaloids, opiates, adrenergic antagonists, NSAIDs or
antibodies) known in the art. In some embodiments, a therapeutic
effect may be greater as compared to use of rimegepant or one or
more additional agent(s) alone. Accordingly, a synergistic effect
between rimegepant and the one or more additional agents may be
achieved. In some embodiments, the one or more additional agent(s)
may be taken by a subject prophylactically.
[0072] In addition to migraine, other CGRP related disorders that
may be treated by the pharmaceutical compositions and methods of
the present invention include, for example, cluster headache;
chronic tension type headache; chronic pain; neurogenic
inflammation and inflammatory pain; eye pain; tooth pain;
non-insulin dependent diabetes mellitus; vascular disorders;
inflammation; arthritis; bronchial hyperreactivity; asthma; shock;
sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes
in men and women; allergic dermatitis; psoriasis; encephalitis,
brain trauma, ischaemia, stroke, epilepsy, and neurodegenerative
diseases; skin diseases; neurogenic cutaneous redness, skin
rosaceousness and erythema; tinnitus; obesity; inflammatory bowel
disease; irritable bowel syndrome; and cystitis.
[0073] In one aspect, the invention also provides kits for use in
the instant methods. Kits can include one or more containers
comprising a pharmaceutical composition described herein and
instructions for use in accordance with any of the methods
described herein. Generally, these instructions comprise a
description of administration of the pharmaceutical composition to
treat, ameliorate or prevent headache (such as migraine), or other
CRGP disorder, according to any of the methods described herein.
The kit may, for example, comprise a description of selecting an
individual suitable for treatment based on identifying whether that
individual has headache or whether the individual is at risk of
having headache. The instructions are typically provided in the
form of a package insert, or label, in accordance with the
requirements of the regulatory having authority over the
jurisdiction where the pharmaceutical composition is to be provided
to patients.
[0074] In accordance with the present invention, administration of
the pharmaceutical compositions comprising rimegepant to a subject
may promote a reduction in severity (which can include reducing
need for and/or amount of (e.g., exposure to) other drugs and/or
therapies generally used for this condition, including, for
example, ergotamine, dihydroergotamine, or triptans for migraine),
duration, and/or frequency (including, for example, delaying or
increasing time to next episodic attack in an individual).
[0075] In addition, administration of the pharmaceutical
compositions comprising rimegepant to a subject may promote a
lessening or improvement of one or more symptoms of headache, or a
reduction in the duration of a symptom, as compared to not
administering a treatment.
[0076] In addition, administration of the pharmaceutical
compositions comprising rimegepant to a subject may promote a
reduction in the frequency of headache attacks in an individual (as
compared to the level before treatment) in a certain time period,
e.g., per month. For example, the frequency of attacks may be
reduced by at least about any of 10%, 20%, 30%, 40%, 50%, 60%, or
70% in the individual as compared to the level before
treatment.
[0077] In addition, administration of the pharmaceutical
compositions comprising rimegepant to a subject may promote a delay
in the development of headache, i.e., to defer, hinder, slow,
retard, stabilize, and/or postpone progression of the disease. This
delay can be of varying lengths of time, depending on the history
of the disease and/or individuals being treated.
[0078] In addition, administration of the pharmaceutical
compositions comprising rimegepant to a subject may delay the
development or progression of a headache, i.e., delay of the
initial manifestations and/or ensuing progression of the disorder.
Development of headache can be detectable and assessed using
standard clinical techniques as well known in the art. However,
development also refers to progression that may be
undetectable.
EXAMPLES
[0079] The following examples illustrate the invention and are not
intended to limit the scope of the invention.
Example 1
[0080] Tablet Manufacture--A batch is prepared to manufacture
tablets containing a dose of 75 mg of rimegepant as follows. The
composition of the batch is set forth below in Table 1. Tablets are
made from the batch as indicated.
TABLE-US-00001 TABLE 1 Amount per Percent Amount 100,000 per per
Tablet, Tablet Ingredient Tablet (mg) Batch (g) Intra-granular
Rimegepant (as hemisulfate 57.11 85.67 8575.5 sesquihydrate
equivalent to 75 mg as base) Microcrystalline cellulose, NF 13.39
20.09 2,011.0 Hydroxypropyl Cellulose), USP/ 4.00 6.00 600.6 NF
(Klucel EXF PHARM) Croscarmellose Sodium NF 2.50 3.75 375.4
Purified Water USP q.s. N/A 0.sup.1 Intragranular Dispensed Solids
11562 Extra-granular Microcrystalline cellulose NF 20.00 30.00
3,003.0 Croscarmellose Sodium NF 2.50 3.75 375.4 Magnesium Stearate
NF 0.50 0.75 75.08 Total Core Tablet 100.0 150 15015 .sup.1Purified
Water is removed in-process. An excess amount is dispensed. The
portion consumed is documented. Intragranular Dispensed Solids does
not include water.
[0081] 1. The rimegepant hemisulfate sesquihydrate and all
excipients are weighed. [0082] 2. Pass the rimegepant hemisulfate
sesquihydrate, microcrystalline cellulose (intragranular portion),
hydroxypropyl cellulose, and croscarmellose sodium (intragranular
portion) through a 20-mesh screen. [0083] 3. Load the sieved
mixture from 2 into a suitable granulator equipped with an
appropriate size bowl & dry mix for 10 minutes. Set impeller
speed to low & turn chopper off. [0084] 4. While mixing, equip
the granulator with a spray tip and add purified water until
endpoint is reached. [0085] 5. Mix wet mass for 30 seconds with
impeller set to low and chopper set to low. [0086] 6. Discharge the
wet mass into expansion chamber of fluid bed dryer. Dry to target
LOD of <2%. [0087] 7. Mill the dried granules using the Comil
with an appropriate screen (0.075R) and spacer (0.050). Perform
bulk and tapped density & particle size distribution analyses.
Record results. Calculate Carr Index & Carr Index mean from two
samples. [0088] 8. Calculate the fractional yield. Recalculate the
extragranular quantities. [0089] 9. Pass the microcrystalline
cellulose and croscarmellose through a 20-mesh screen. [0090] 10.
Combine the milled granulation with the recalculated
microcrystalline cellulose (extragranular portion), croscarmellose
sodium (extragranular portion) in a 2-cubic foot tote & blend
for 150 revolutions. [0091] 11. Pass the magnesium stearate through
30-mesh screen. [0092] 12. Add screened magnesium stearate to the 2
cubic foot tote contents & blend for 75 revolutions. [0093] 13.
Collect blend uniformity samples per plan. [0094] 14. Perform bulk
& tapped density and particle size analyses & calculate
Carr Index. [0095] 15. Discharge into a suitable container and
weigh. [0096] 16. Set up 716-station rotary tablet press with 7 mm
round concave plain tooling. Adjust number of stations as needed.
[0097] 17. Adjust the press to achieve the following specifications
for the tablets: Friability of 0.3% loss; Hardness of 10-14 kP;
Thickness of 3.60-4.10 mm; and Disintegration of 2:30 minutes.
[0098] 18. Conduct in-process testing as follows: [0099] Tablet
friability and disintegration at beginning, middle and end of run
[0100] Tablet hardness, tablet thickness, individual tablet
weights, average tablet weights, and appearance at 15 minute
intervals [0101] 19. Pass the tablets through a de-duster and metal
detector. [0102] 20. Package tablets in double polyethylene bags in
a suitable container.
Example 2
Clinical Trial--BHV3000-301: Phase 3: Double-Blind, Randomized,
Placebo-Controlled, Safety and Efficacy Trial of BHV-3000
(Rimegepant) for the Acute Treatment of Migraine
(ClinicalTrials.gov Identifier: NCT03235479).
[0103] A phase 3 clinical study was conducted with 1490
participants, as follows.
Study Description
[0104] The purpose of this study was to compare the efficacy of
BHV-3000 (rimegepant) versus placebo in subjects with Acute
Migraines
TABLE-US-00002 Condition or disease Intervention/treatment Migraine
Drug: BHV-3000 Acute Migraine Drug: Placebo Oral Tablet Phonophobia
Photophobia
Study Design
[0105] Study Type: Interventional (Clinical Trial) [0106] Actual
Enrollment: 1490 participants [0107] Allocation: Randomized [0108]
Intervention Model: Parallel Assignment [0109] Intervention Model
Description: Double-blind to Sponsor, Investigator and Subject
Randomized Controlled Trial [0110] Masking: Triple (Participant,
Care Provider, Investigator) [0111] Masking Description:
Double-blind to Sponsor, Investigator and Subject [0112] Primary
Purpose: Treatment [0113] Official Title: BHV3000-301: Phase 3:
Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy
Trial of BHV-3000 (Rimegepant) for the Acute Treatment of
Migraine
Arms and Interventions
TABLE-US-00003 [0114] Arm Intervention/treatment Experimental:
Drug: BHV-3000 BHV-3000 75 mg tablet QD Placebo Comparator: Drug:
Placebo Oral Tablet Placebo equivalent of 75 mg tablet QD
Outcome Measures
Primary Outcome Measures:
[0115] 1. Pain freedom of rimegepant (75 mg tablet) compared with
placebo in the acute treatment of migraine will be measured using
the number of evaluable subjects that report no pain at 2 hours
post-dose. [Time Frame: Two hours post dose] [0116] Pain will be
measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate,
3=severe) [0117] 2. Freedom from the most bothersome symptom (MBS)
of rimegepant (75 mg tablet) compared with placebo will be measured
using the number of evaluable subjects that report the absence of
their MBS at 2 hours post-dose. [Time Frame: Two hours post dose]
[0118] The MBS (nausea, phonophobia or photophobia) will measured
using a binary scale (0=absent, 1=present).
Secondary Outcome Measures:
[0118] [0119] 1. To measure the difference between rimegepant (75
mg tablet) compared to placebo from 2 to 24 hours, using the number
of subjects that do not experience any headache pain through the
time period of interest. [Time Frame: 2 hours -24 hours post-dose]
[0120] Sustained Pain Freedom as measured by a 4 point numeric
rating scale (None, Mild, Moderate, Severe) [0121] 2. The
difference between rimegepant (75 mg tablet) compared to placebo by
tabulating the absence of photophobia at 2 hours post-dose in the
subset of subjects that reported the presence of photophobia at
headache baseline. [Time Frame: 2 hours post-dose] [0122]
Photophobia [0123] 3. To evaluate rimegepant (75 mg tablet)
compared to placebo by tabulating the number of subjects that
report the absence of phonophobia at 2 hours post-dose in the
subset of subjects that reported the presence of phonophobia at
headache baseline. [Time Frame: 2 hours post-dose] [0124]
Phonophobia [0125] 4. To measure the difference between rimegepant
(75 mg tablet) compared to placebo on Pain Relief, at 2 hours
post-dose, for those that report a pain level of moderate or severe
at baseline and then report a pain level of none or mild. [Time
Frame: 2 hours post-dose] [0126] Pain Relief as measured by a 4
point numeric rating scale (None, Mild, Moderate, Severe) [0127] 5.
Freedom from Nausea by tabulating the number of subjects that
report the absence of nausea at 2 hours post-dose in the subset of
subjects that reported the presence of nausea at headache baseline.
[Time Frame: 2 hours post-dose] [0128] Freedom from Nausea [0129]
6. The difference between rimegepant (75 mg tablet) compared to
placebo on the probability of requiring rescue medication using the
number of subjects that take rescue medication within 24 after
administration of study medication (BHV3000 or placebo). [Time
Frame: up to 24 hours post-dose] [0130] Requiring Rescue Medication
[0131] 7. To measure the difference between rimegepant (75 mg
tablet) compared to placebo on sustained pain freedom, from 2 to 48
hours, using the number of subjects that do not experience any
headache pain through the time period of interest. [Time Frame: 2
hours-24 hours post-dose] [0132] Sustained Pain Freedom [0133] 8.
Rimegepant (75 mg tablet) compared to placebo on sustained pain
relief, from 2 to 24 hours by using the number of subjects that do
not use any rescue medications, and do not experience any moderate
or severe headache pain through that time. [Time Frame: 2 hours-24
hours post-dose] [0134] Sustained Pain Relief as measured by a 4
point numeric rating scale (None, Mild, Moderate, Severe) [0135] 9.
To measure the difference between rimegepant (75 mg tablet)
compared to placebo on sustained pain relief from 2 to 48 hours,
using the number of subjects that do not use any rescue medications
and do not experience moderate to severe headache pain. [Time
Frame: 2 hours-48 hours post-dose] [0136] Sustained Pain Relief as
measured by a 4 point numeric rating scale (None, Mild, Moderate,
Severe) [0137] 10. To measure the difference between rimegepant (75
mg tablet) relative to placebo on the proportion of subjects able
to function normally, at 2 hours, using the number of subjects that
self-report as "normal" on the functional disability scale. [Time
Frame: 2 hours post-dose] [0138] Functional Disability Score [0139]
11. To measure the difference between rimegepant (75 mg tablet)
compared to placebo on pain relapse using the number of subjects
that are pain free at 2 hours post-dose and then have a headache of
any severity within 48 hours of study medication. [Time Frame: 2
hours to 48 hours post-dose] [0140] Pain relapse as measured by a 4
point numeric rating scale (None, Mild, Moderate, Severe)
[0141] Further details concerning the clinical study including
eligibility criteria, contacts and locations and more information
can be found at www.clinicaltrials.gov for ClinicalTrials.gov
Identifier: NCT03235479.
Example 3
Clinical Trial--BHV3000-302: Phase 3: Double-Blind, Randomized,
Placebo-Controlled, Safety and Efficacy Trial of BHV-3000
(Rimegepant) for the Acute Treatment of Migraine
(ClinicalTrials.gov Identifier: NCT03237845)
[0142] A phase 3 clinical study was conducted with 1503
participants, as follows.
Study Description
Brief Summary:
[0143] The purpose of this study is to compare the efficacy of
BHV-3000 (rimegepant) versus placebo in subjects with Acute
Migraines
TABLE-US-00004 Condition or disease Intervention/treatment Migraine
Drug: BHV-3000 Acute Migraine Drug: Placebo Oral Tablet Phonophobia
Photophobia
Study Design
[0144] Study Type: Interventional (Clinical Trial) [0145] Actual
Enrollment: 1503 participants [0146] Allocation: Randomized [0147]
Intervention Model: Parallel Assignment [0148] Intervention Model
Description: Double-blind to Sponsor, Investigator and Subject
[0149] Masking: Triple (Participant, Care Provider, Investigator)
[0150] Masking Description: Double-blind to Sponsor, Investigator
and Subject [0151] Primary Purpose: Treatment [0152] Official
Title: BHV3000-302: Phase 3: Double-Blind, Randomized,
Placebo-Controlled, Safety and Efficacy Trial of BHV-3000
(Rimegepant) for the Acute Treatment of Migraine [0153] Actual
Study Start Date: Jul. 26, 2017 [0154] Primary Completion Date:
Jan. 25, 2018 [0155] Study Completion Date: Jan. 31, 2018
Arms and Interventions
TABLE-US-00005 [0156] Arm Intervention/treatment Experimental:
BHV-3000 Drug: Rimegepant rimegepant 75 mg tablet QD active Placebo
Comparator: Placebo Drug: Placebo Matching 75 mg placebo tablet QD
placebo
Outcome Measures
Primary Outcome Measures:
[0157] 1. Pain Freedom of rimegepant (75 mg tablet) compared with
placebo in the acute treatment of migraine will be measured using
the number of evaluable subjects that report no pain at 2 hours
post-dose. [Time Frame: Two hours post dose] [0158] Pain will be
measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate,
3=severe) [0159] 2. Freedom from the most bothersome symptom (MBS)
of rimegepant (75 mg tablet) compared with placebo will be measured
using the number of evaluable subjects that report the absence of
their MBS at 2 hours post-dose. [Time Frame: Two hours post dose]
[0160] The MBS (nausea, phonophobia or photophobia) will measured
using a binary scale (0=absent, 1=present).
Secondary Outcome Measures:
[0160] [0161] 1. Rimegepant (75 mg tablet) compared to placebo from
2 to 24 hours, using the number of subjects that do not experience
any headache pain through the time period of interest. [Time Frame:
2 hours -24 hours post-dose] [0162] Sustained Pain Freedom as
measured by a 4 point numeric rating scale (None, Mild, Moderate,
Severe) [0163] 2. Rimegepant (75 mg tablet) compared to placebo by
tabulating the number of subjects that report the absence of
photophobia at 2 hours post-dose in the subset of subjects that
reported the presence of photophobia at headache baseline. [Time
Frame: 2 hours post-dose] [0164] Freedom from Photophobia [0165] 3.
Rimegepant (75 mg tablet) compared to placebo by tabulating the
number of subjects that report the absence of phonophobia at 2
hours post-dose in the subset of subjects that reported the
presence of phonophobia at headache baseline. [Time Frame: 2 hours
post-dose] [0166] Freedom from Phonophobia [0167] 4. To measure
rimegepant (75 mg tablet) compared to placebo on Pain Relief, at 2
hours post-dose, that report a pain level of moderate or severe at
baseline and then report a pain level of none or mild. [Time Frame:
2 hours post-dose] [0168] Pain Relief as measured by a 4 point
numeric rating scale (None, Mild, Moderate, Severe) [0169] 5.
Freedom from Nausea will by tabulating the number of subjects that
report the absence of nausea at 2 hours post-dose in the subset of
subjects that reported the presence of nausea at headache baseline.
[Time Frame: 2 hours post-dose] [0170] Freedom from Nausea [0171]
6. To measure rimegepant (75 mg tablet) compared to placebo on the
probability of requiring rescue medication will be assessed using
the number of subjects that take rescue medication within 24 after
administration of study medication (BHV3000 or placebo). [Time
Frame: up to 24 hours post-dose] [0172] Requiring Rescue Medication
[0173] 7. Rimegepant (75 mg tablet) compared to placebo on
sustained pain freedom, from 2 to 48 hours, will be measured using
the number of subjects that do not experience any headache pain
through the time period of interest. [Time Frame: 2 hours-48 hours
post-dose] [0174] Sustained Pain Freedom as measured by a 4 point
numeric rating scale (None, Mild, Moderate, Severe) [0175] 8.
Rimegepant (75 mg tablet) compared to placebo on sustained pain
relief, from 2 to 24 hours by using the number of subjects that do
not use any rescue medications, and do not experience any moderate
or severe headache pain through that time. [Time Frame: 2 hours-24
hours post-dose] [0176] Sustained Pain Relief as measured by a 4
point numeric rating scale (None, Mild, Moderate, Severe) [0177] 9.
Rimegepant (75 mg tablet) compared to placebo on sustained pain
relief from 2 to 48 hours, using the number of subjects that do not
use any rescue medications and do not experience moderate to severe
headache pain. [Time Frame: 2 hours-48 hours post-dose] [0178]
Sustained Pain Relief as measured by a 4 point numeric rating scale
(None, Mild, Moderate, Severe) [0179] 10. Rimegepant (75 mg tablet)
relative to placebo on the proportion of subjects able to function
normally, at 2 hours, using the number of subjects that self-report
as "normal" on the functional disability scale. [Time Frame: 2
hours post-dose] [0180] Functional Disability Score [0181] 11.
Rimegepant (75 mg tablet) compared to placebo on pain relapse will
be measured using the number of subjects that are pain free at 2
hours post-dose and then have a headache of any severity within 48
hours of study medication. [Time Frame: 2 hours to 48 hours
post-dose] [0182] Pain relapse as measured by a 4 point numeric
rating scale (None, Mild, Moderate, Severe)
[0183] Further details concerning the clinical study including
eligibility criteria, contacts and locations and more information
can be found at www.clinicaltrials.gov for ClinicalTrials.gov
Identifier: NCT03237845.
Example 4
[0184] Results from Clinical Trials--The study results from the
clinical studies described in Example 2 and Example 3 are set forth
in FIG. 1, FIG. 2 and Table 2, Table 3 and Table 4.
TABLE-US-00006 TABLE 2 Co-Primary Endpoints Met in Both Phase 3
Trials Rimegepant Placebo Adjusted 2 hour Endpoint (N = 537) (N =
535) p-value Study 302 Pain Freedom 19.6% 12.0% <0.001 Freedom
from MBS.sup.1 37.6% 25.2% <0.0001 Rimegepant Placebo Adjusted 2
hour Endpoint (N = 543) (N = 541) p-value Study 301 Pain Freedom
19.2% 14.2% <0.03 Freedom from MBS.sup.1 36.6% 27.7% <0.002
.sup.1Most Bothersome Symptom including Photophobia, Phonophobia or
Nausea
TABLE-US-00007 TABLE 3 Pain Freedom: Increasing Benefit Over Time
Single Dose of Rimegepant, No Rescue Meds (Study 302) Pain Freedom
2-8 Hours Post-Single Dosing with Rimegepant 75 mg Percent (%)
difference of Patients Pain Free: Time Point Rimegepant (n = 537)
(hours) versus Placebo (n = 535) 2 7 3 13 4 19 6 22 8 19 Data are
Kaplan-Meier estimates of pain freedom; subjects were censored (not
included) who took rescue medication or were lost to follow-up
during the specified interval
TABLE-US-00008 TABLE 4 Pooled Liver Function Test (LFT) Profile:
Rimegepant was Similar to Placebo in Both Studies Complete Dataset
of LFT Results from Study 301 and Study 302 Rimegepant Placebo (n =
1089) (n = 1092) ALT >ULN 22 (2.0%) 24 (2.2%) >3.times. ULN 1
(0.1%) 1 (0.1%) >5.times. ULN 0 0 >10.times. ULN 0 0
>20.times. ULN 0 0 AST >ULN 12 (1.1%) 16 (1.5%) >3.times.
ULN 1 (0.1%) 0 >5.times. ULN 0 0 >10.times. ULN 0 0
>20.times. ULN 0 0 *No bilirubin elevations >2.times. ULN
across both Studies 301 and 302 *ALL CASES RESOLVED
Example 5
[0185] Bioequivalence--The bioequivalence of an oral solid molded
fast-dispersing dosage form made with fish gelatin as described
herein ("ODT") at a dose of 75 mg of rimegepant was compared to the
75 mg tablets used in the studies described in Examples 2 and
3.
[0186] The synopsis of the experiment is set forth below.
Primary Objective:
[0187] To compare the rate and extent of absorption of rimegepant
ODT administered sublingually versus rimegepant tablet administered
as 1.times.75 mg in healthy volunteers under fasting
conditions.
Secondary Objective:
[0188] To assess the safety, tolerability, and PK of rimegepant
tablet and ODT.
Exploratory Objective:
[0189] To compare the rate and extent of absorption of rimegepant
ODT administered on top of the tongue versus rimegepant tablet
administered as 1.times.75 mg in healthy volunteers under fasting
conditions.
Study Design
[0190] This will be a single center, Phase 1, open-label,
randomized study designed to be conducted as follows:
[0191] Part I: 4-period, 2-sequence, fully-replicated crossover
bioequivalence study.
[0192] Part II: 2-period, 2-sequence, crossover relative
bioavailability study. Part II may be conducted prior to Part
I.
[0193] This study is intended for filing under Food and Drug
Administration (FDA), European Medicines Agency (EMA), and Health
Product and Food Branch (HPFB) regulations.
[0194] Each part of the study is intended to dose in one group; if,
for any reason, either of the study parts is dosed in more than one
group, all groups will be dosed at the same clinical site and the
same protocol requirements and procedures will be followed within
each group.
Sample Size
[0195] A total of approximately 60 healthy adult male or female
volunteers will be dosed. Approximately 36 subjects will be
included in the Part I bioequivalence portion of the study. Based
on preliminary data from previous studies, the intra-subject
coefficient of variation should be approximately 30% for both AUC
and C.sub.max. Thus, with this expected coefficient of variation
and an expected ratio of AUC and C.sub.max within 0.91 and 1.10,
the study should have a power of at least 80% to show
bioequivalence with 30 subjects in a 4-period fully replicated
design. In order of the study.
[0196] Approximately 24 subjects will be included in the Part II
relative bioavailability portion of the study.
Confinements and Washouts
[0197] Part I
[0198] Subjects will be confined from at least 10 hours before drug
administration of Period 1 until after the 72-hour post-dose blood
draw of Period 4, i.e., until morning of Day 22.
[0199] There will be a washout period of 5 days or more between
doses; subjects will remain confined in the clinic throughout the
washout periods. Participation of each subject in this study should
last approximately 3 weeks.
[0200] Part II
[0201] Subjects will be confined from at least 10 hours before drug
administration of Period 1 until after the 72-hour post-dose blood
draw of Period 2, i.e., until morning of Day 8.
[0202] There will be a washout period of 4 days or more between
doses; subjects will remain confined in the clinic throughout the
washout periods. Participation of each subject in this study should
last approximately 1.5 weeks.
Randomization and Blinding
[0203] Subjects will be administered each treatment according to
the 4-period, 2-sequence (CBCB or BCBC) and to the 2-period,
2-sequence (CA or AC), block randomization scheme produced by
inVentiv for Part I and Part II, respectively. The randomization
code will not be available to the Bioanalytical Division of
inVentiv until the clinical and analytical phases of the study have
been completed.
[0204] This study will be open-label due to the objective nature of
the data.
Study Medication
[0205] Part I
[0206] Each subject will receive each of the 2 following treatments
twice:
[0207] Treatment C (Test): 1.times.75 mg rimegepant sublingual ODT
to be held under the tongue until fully dissolved then swallowed
without water, administered under fasting conditions
[0208] Treatment B (Reference): 1.times.75 mg rimegepant tablet
swallowed with water, administered under fasting conditions
[0209] Part II
[0210] Each subject will receive each of the 2 following treatments
once:
[0211] Treatment C (Test): 1.times.75 mg rimegepant sublingual ODT
to be held under the tongue until fully dissolved then swallowed
without water, administered under fasting conditions
[0212] Treatment A (Reference): 1.times.75 mg rimegepant ODT to be
held on top of the tongue until fully dissolved then swallowed
without water, administered under fasting conditions
[0213] Part I
[0214] Treatment C
[0215] One rimegepant ODT will be placed under each subject's
tongue by the clinical staff and subject will be instructed not to
swallow saliva until the ODT is completely dissolved. The subject
will be instructed to give a hand sign once the ODT is completely
dissolved and swallowed. A hand and mouth check will be performed
to ensure consumption of the medication.
[0216] Time of dosing will be set to the time the ODT is placed
under the tongue. No water will be allowed from 1 hour before
dosing and until 1 hour post-dose. The complete dosing procedure
must be completed within 2 minutes. If the ODT is not completely
dissolved within 2 minutes, the subject will be asked to swallow
with saliva and this will be documented. The start and end time of
complete dosing will be recorded.
[0217] Treatment B
[0218] One rimegepant tablet will be administered to each subject
with 240 mL of water and a hand and mouth check will be performed
to ensure consumption of the medication.
[0219] Part II
[0220] Treatment C
[0221] One rimegepant ODT will be placed under each subject's
tongue by the clinical staff and subject will be instructed not to
swallow saliva until the ODT is completely dissolved. The subject
will be instructed to give a hand sign once the ODT is completely
dissolved and swallowed. A hand and mouth check will be performed
to ensure consumption of the medication.
[0222] Time of dosing will be set to the time the ODT is placed
under the tongue. No water will be allowed from 1 hour before
dosing and until 1 hour post-dose. The complete dosing procedure
must be completed within 2 minutes. If the ODT is not completely
dissolved within 2 minutes, the subject will be asked to swallow
with saliva and this will be documented. The start and end time of
complete dosing will be recorded.
[0223] Treatment A
[0224] One rimegepant ODT will be placed on top of each subject's
tongue by the clinical staff and subject will be instructed not to
swallow saliva until the ODT is completely dissolved. The subject
will be instructed to give a hand sign once the ODT is completely
dissolved and swallowed. A hand and mouth check will be performed
to ensure consumption of the medication.
[0225] Time of dosing will be set to the time the ODT is placed on
the tongue. No water will be allowed from 1 hour before and until 1
hour post-dose. The complete dosing procedure must be completed
within 2 minutes. If the ODT is not completely dissolved within 2
minutes, the subject will be asked to swallow with saliva and this
will be documented. The start and end time of complete dosing will
be recorded.
Sample Collection and Processing
[0226] In each period, a total of 17 blood samples will be drawn
from each subject for pharmacokinetic analyses. Blood samples will
be collected prior to drug administration and 0.083, 0.167, 0.333,
0.5, 0.667, 0.833, 1, 1.5, 2, 2.5, 5, 8, 12, 24, 48, and 72 hours
post-dose (3 mL for each sampling time). The time tolerance window
for blood sample collection will be .+-.29 seconds for all
post-dose samples collected during the confinement period. Sample
collections done outside the pre-defined time windows will not be
considered as protocol deviations since actual post-dose sampling
times will be used for pharmacokinetic and statistical analyses.
Unless otherwise specified or for subject safety, when blood draws
and other procedures coincide, blood draws will have precedence. A
dead-volume intravenous catheter will be used for blood collection
to avoid multiple skin punctures, when appropriate. Otherwise,
blood samples will be collected by direct venipuncture.
[0227] The total volume of blood including that collected for
eligibility, genotyping, and safety purposes should not exceed 308
mL for Part I and 185 mL for Part II.
[0228] Plasma samples will be collected and processed.
Pharmacokinetic and Statistical Analyses
[0229] PK analysis will be performed using Phoenix.RTM.
WinNonlin.RTM., which is validated for
bioequivalence/bioavailability studies. Inferential statistical
analyses will be performed using SAS.RTM. according to FDA, EMA,
and HPFB guidelines.
[0230] Bioanalysis of all samples should be completed prior to the
initiation of the pharmacokinetic and statistical analyses.
Pharmacokinetics
[0231] The following PK parameters will be calculated by standard
non-compartmental methods for rimegepant: [0232] AUC.sub.0-t: area
under the concentration-time curve from time zero to the last
non-zero concentration [0233] AUC.sub.0-inf: area under the
concentration-time curve from time zero to infinity (extrapolated)
[0234] C.sub.max: maximum observed concentration [0235] Residual
area: calculated as 100*(1-AUC.sub.0-t/AUC.sub.0-inf) [0236]
T.sub.max: time of observed C.sub.max [0237] T1/2.sub.el:
elimination half-life [0238] K.sub.el: elimination rate
constant
[0239] Additional PK analysis may be performed.
Safety Population
[0240] The safety population is defined as all subjects who
received at least one dose of the study medication.
Pharmacokinetic Population
[0241] For Part I, the pharmacokinetic population will include all
subjects completing at least 2 periods, including Treatment C and
Treatment B, and for whom the pharmacokinetic profile can be
adequately characterized.
[0242] For Part II, the pharmacokinetic population will include all
subjects completing the study and for whom the pharmacokinetic
profile can be adequately characterized.
[0243] Any subject with pre-dose concentrations will be presented
in the concentrations and PK tables but excluded from descriptive
statistics and inferential analyses (for the concerned period in
Part I) if the pre-dose concentration is greater than 5% of the
C.sub.max value measured for that subject.
[0244] Data from subjects who experienced emesis during the
sampling interval and who were not withdrawn may be evaluated after
completion of the PK analysis. Any subject who experienced emesis
within 2 times median T.sub.max of rimegepant will be excluded from
the statistical analysis (i.e., descriptive statistics and
inferential analyses). Similarly, subjects withdrawn due to AEs or
vomiting episodes will be presented in data listings but excluded
from the statistical analysis tables (for the concerned period in
Part I).
Statistical Analyses
[0245] A Statistical Analysis Plan (SAP) will be prepared after
completion of the final protocol and finalized prior to database
lock.
[0246] Demographic parameters will be summarized descriptively.
Treatment-emergent adverse events (TEAEs) will be summarized
descriptively by treatment for all subjects who were dosed (safety
population). No inferential statistical analysis of safety data is
planned.
[0247] Individual and mean plasma concentration versus time curves
will be presented for both linear and semi-log scales. Descriptive
statistics (arithmetic and geometric means, standard deviation
[SD], coefficient of variation [CV %], minimum [Min], maximum
[Max], and median) of the plasma concentrations and the PK
parameters will be presented.
[0248] The results of the bioequivalence experiment are set forth
in Table 5, Table 6 and Table 7.
TABLE-US-00009 TABLE 5 Summary Descriptive Statistics of BHV3000
for Pharmacokinetic Parameters by Treatment and Administration -
Part I AUC0_15 min AUC0_30 min AUC0_1 h AUC0_2 h AUC.sub.0-t
AUC.sub.0-inf Analyte Admin Treatment Sequence (hr*ng/mL)
(hr*ng/mL) (hr*ng/mL) (hr*ng/mL) (hr*ng/mL) (hr*ng/mL) BHV3000 1
Rimegepant N 34 34 34 34 34 34 ODT (Test) Mean 3.33 48.61 316.30
1049.14 4973.13 4986.40 SD 5.25 54.43 251.82 500.98 1429.06 1429.42
CV % 157.92 111.96 79.61 47.75 28.74 28.67 Min 0.00 0.00 1.28
301.45 2707.35 2717.72 Median 0.95 25.58 280.40 1041.73 4539.82
4547.99 Max 24.49 179.44 911.21 2171.04 8132.62 8147.14 Geometric
NC NC 181.16 927.52 4773.19 4787.03 Mean BHV3000 2 Rimegepant N 33
33 33 33 33 33 ODT (Test) Mean 3.37 51.96 320.86 1030.22 5339.16
5354.99 SD 4.44 55.31 242.39 532.43 1512.51 1514.60 CV % 131.57
106.44 75.54 51.68 28.33 28.28 Min 0.01 0.50 3.30 103.79 2344.91
2356.32 Median 1.38 29.25 255.77 1082.04 5408.31 5421.88 Max 18.95
210.33 753.99 2029.77 8855.17 8866.97 Geometric 0.98 20.27 197.12
847.73 5125.96 5141.76 Mean BHV3000 1 Rimegepant N 34 34 34 34 34
34 Tablet (Ref) Mean 0.68 19.87 232.43 924.82 5201.88 5215.35 SD
0.88 19.95 186.00 514.64 1552.87 1552.78 CV % 128.78 100.37 80.03
55.65 29.85 29.77 Min 0.00 0.05 4.19 75.32 2635.48 2649.68 Median
0.43 14.61 184.61 966.91 4838.68 4863.29 Max 3.91 98.96 608.73
1957.51 9551.54 9565.90 Geometric NC 9.51 139.80 743.54 4992.61
5006.58 Mean BHV3000 2 Rimegepant N 33 33 33 33 33 33 Tablet (Ref)
Mean 1.13 25.37 259.64 950.90 5493.72 5509.22 SD 1.74 30.78 181.00
459.51 1670.65 1674.11 CV % 154.86 121.33 69.71 48.32 30.41 30.39
Min 0.00 0.29 5.44 84.31 2916.65 2936.35 Median 0.31 11.41 226.97
889.26 5272.46 5293.49 Max 6.89 121.36 732.48 2008.09 9819.52
9864.26 Geometric NC 11.38 186.64 811.20 5258.65 5274.04 Mean
Residual C.sub.max T.sub.max T.sub.1/2 K.sub.el Analyte Admin
Treatment Sequence area (%) (ng/mL) (hr) (hr) (1/hr) BHV3000 1
Rimegepant N 34 34 34 34 34 ODT (Test) Mean 0.29 904.02 1.47 7.84
0.0921 SD 0.18 319.43 0.64 1.56 0.0190 CV % 63.45 35.34 43.30 19.93
20.6076 Min 0.09 292.92 0.67 5.75 0.0664 Median 0.22 916.06 1.50
8.11 0.0855 Max 1.06 1855.84 2.50 10.44 0.1205 Geometric 0.25
849.54 1.34 7.68 0.0902 Mean BHV3000 2 Rimegepant N 33 33 33 33 33
ODT (Test) Mean 0.31 915.87 1.54 8.69 0.0835 SD 0.16 308.35 0.70
1.83 0.0189 CV % 52.24 33.67 45.10 21.04 22.6469 Min 0.12 377.61
0.67 5.73 0.0540 Median 0.25 920.80 1.50 8.54 0.0812 Max 0.64
1529.91 2.50 12.84 0.1210 Geometric 0.27 861.48 1.38 8.50 0.0816
Mean BHV3000 1 Rimegepant N 34 34 34 34 34 Tablet (Ref) Mean 0.28
907.50 2.04 7.98 0.0910 SD 0.16 366.37 1.24 1.73 0.0199 CV % 57.73
40.37 60.80 21.74 21.8434 Min 0.09 338.78 0.67 5.51 0.0603 Median
0.22 910.77 2.00 8.06 0.0860 Max 0.86 2204.05 5.00 11.50 0.1257
Geometric 0.24 841.03 1.75 7.79 0.0889 Mean BHV3000 2 Rimegepant N
33 33 33 33 3 Tablet (Ref) Mean 0.29 834.10 1.83 8.60 0.0833 SD
0.15 289.63 0.88 1.50 0.0164 CV % 50.78 34.72 48.30 17.39 19.6372
Min 0.12 386.15 0.67 5.89 0.0624 Median 0.28 798.82 1.50 8.49
0.0817 Max 0.71 1671.55 5.00 11.10 0.1176 Geometric 0.26 786.69
1.64 8.46 0.0819 Mean
TABLE-US-00010 TABLE 6 Summary Descriptive Statistics of BHV3000
for Pharmacokinetic Parameters by Treatment - Part I AUC0_15 min
AUC0_30 min AUC0_1 h AUC0_2 h AUC.sub.0-t AUC.sub.0-inf Analyte
Treatment (hr*ng/mL) (hr*ng/mL) (hr*ng/mL) (hr*ng/mL) (hr*ng/mL)
(hr*ng/mL) BHV3000 Rimegepant N 67 67 67 67 67 67 Sublingual ODT
(Test) Mean 3.35 50.26 318.55 1039.82 5153.41 5167.94 SD 4.83 54.47
245.35 512.86 1471.15 1472.53 CV % 144.27 108.38 77.02 49.32 28.55
28.49 Min 0.00 0.00 1.28 103.79 2344.91 2356.32 Median 1.26 29.16
267.11 1082.04 4956.26 4963.67 Max 24.49 210.33 911.21 2171.04
8855.17 8866.97 Geometric NC NC' 188.85 887.32 4943.80 4958.58 Mean
BHV3000 Rimegepant N 67 67 67 67 67 67 ODT (Test) Mean 0.90 22.58
245.83 937.67 5345.62 5360.09 SD 1.38 25.81 182.68 484.74 1606.41
1608.21 CV % 153.46 114.29 74.31 51.70 30.05 30.00 Min 0.00 0.05
4.19 75.32 2635.45 2649.68 Median 0.34 14.03 218.33 899.23 5093.43
5104.27 Max 6.89 121.36 732.48 2008.09 9819.52 9864.26 Geometric NC
10.39 161.18 776.17 5121.92 5136.57 Mean Residual C.sub.max
T.sub.max T.sub.1/2 K.sub.el Analyte Treatment area (%) (ng/mL)
(hr) (hr) (1/hr) BHV3000 Rimegepant N 67 67 67 67 67 Sublingual ODT
(Test) Mean 0.30 909.86 1.50 8.26 0.0879 SD 0.17 311.69 0.66 1.74
0.0193 CV % 57.53 34.26 44.00 21.07 21.9579 Min 0.09 292.92 0.67
5.73 0.0540 Median 0.24 920.80 1.50 8.39 0.0827 Max 1.06 1855.84
2.50 12.84 0.1210 Geometric 0.26 855.40 1.36 8.07 0.0859 Mean
BHV3000 Rimegepant N 67 67 67 67 67 ODT (Test) Mean 0.29 871.35
1.94 8.28 0.0872 SD 0.15 330.38 1.08 1.64 0.0185 CV % 53.91 37.92
55.60 19.78 21.2192 Min 0.09 338.78 0.67 5.51 0.0603 Median 0.25
851.12 2.00 8.40 0.0825 Max 0.86 2204.05 5.00 11.50 0.1257
Geometric 0.25 813.81 1.69 8.12 0.0854 Mean
TABLE-US-00011 TABLE 7 Ratios, 90% Geometric Confidence Intervals,
CV.sub.WR (FDA Methodology) 90% 90% 95% Upper Lower Upper
Confidence PK Ratio.sup.1 C.I..sup.2 C.I..sup.2 Bounds.sup.3
CV.sub.WR Parameter (%) (%) (%) (%) (%) Ln(AUC.sub.0-t) 96.79 92.63
101.15 -- 15.70 Ln(AUC.sub.0-inf) 96.81 92.66 101.14 -- 15.68
Ln(C.sub.max) 104.65 97.04 112.84 -- 23.74 .sup.1Calculated using
least-squares means according to the formula: e.sup.(DIFFERENCE)
.times. 100. .sup.290% Geometric Confidence Interval using
In-transformed data. .sup.3Reference Scaled ABE approach.
Example 6
[0249] Efficacy of Rimegepant--Results and analysis from the
Clinical Trial--BHV3000-301 described in Example 2.
[0250] Objectives
[0251] To compare the efficacy, safety, and tolerability of
rimegepant 75 mg oral tablet with placebo in the acute treatment of
migraine in adults.
[0252] Methods
[0253] In a double-blind, randomized, placebo-controlled,
multicenter study (Study 301, NCT03235479) adults 3.8 years of age
with at least a 1-year history of ICHD 3-beta migraine were
eligible to participate. Following a 3- to 28-day screening period,
subjects were randomized to receive rimegepant 75 mg or matching
placebo and instructed to treat a single migraine attack with 1
dose of the blinded study drug (rimegepant or placebo) when
headache pain reached moderate or severe intensity. The coprimary
endpoints were pain freedom at 2 hours postdose and freedom from
the most bothersome symptom (MBS) at 2 hours postdose. Safety
assessments included adverse events (AEs), ECGs, vital signs,
physical measurements, and routine laboratory tests, including
assessment of liver function. Unless stated otherwise, values
presented are mean.+-.SD.
[0254] Results
[0255] In total, 1162 subjects were randomized to receive
rimegepant (n=582) or placebo (n=580), and 1084 were evaluated for
efficacy (rimegepant n=543, placebo n=541). Subjects had a mean age
of 41.6.+-.12.2 years, 85.5% were female, and by history had
4.7.+-.1.8 attacks per month. At 2 hours postdose, rimegepant
treated patients had higher pain-free rates than placebo treated
patients (19.2% vs 14.2%, P=0.0298), were more likely to be free of
the MBS (36.6% vs 27.7%, P=0.0016); and had higher rates of pain
relief (56.0% vs 45.7%, P=0.0006). A single dose of rimegepant,
without the use of rescue medication, demonstrated superiority
versus placebo for sustained pain freedom and pain relief from 2
through 48 hours postdose (P=0.013 and P=0.0003, respectively). On
a measure of functional disability, a greater proportion of
rimegepant-treated patients achieved normal function at 2 hours
(P<0.0001).
[0256] The safety and tolerability profiles of rimegepant were
similar to placebo. The most common AEs were nausea (0.9%, 5/546 vs
1.1%, 6/549) and dizziness (0.7%, 4/546 vs 0.4%, 2/549). Serum ALT
or AST levels greater than the upper limit of normal (ULN) were
seen in 2.0% (11/546) and 3.6% (20/549) of subjects treated with
rimegepant and placebo, respectively. One subject in the rimegepant
group (0.2%) and 1 subject in the placebo group (0.2%) had a
transaminase level >3 times ULN, and no subject in either group
had a level >5 times ULN. No bilirubin elevations >2 times
ULN were observed. Serious AEs (SAEs) were observed in 0.4% (n=2)
of subjects in the rimegepant group and 0.2% (n=1) in the placebo
group. No SAE was determined to be related to the study drug. Both
subjects with SAEs in the rimegepant group had not been dosed
before onset of the SAEs.
[0257] Conclusions
[0258] Significant and durable clinical effects were seen with a
single dose of rimegepant across multiple outcome measures,
including pain freedom, freedom from MBS, pain relief, and recovery
of normal function. Rimegepant 75 mg oral tablet demonstrated
favorable tolerability and safety, including a liver safety profile
similar to placebo. These clinically meaningful results complement
the benefits seen in an identical Phase 3 study (Study 302) and a
previous Phase 2b study. Rimegepant may ultimately offer patients a
novel approach for the acute treatment of migraine.
TABLE-US-00012 Rimegepant Endpoints 75 mg Placebo P-value.sup.a
Coprimary Pain-free at 2 hours 19.2% 14.2% .0298 [104/543] [77/541]
Free from MBS at 2 hours 36.6% 27.7% .0016 [199/543] [150/541]
Selected secondary Photophobia-free at 2 hours 34.9% 24.8% .0005
[164/470] [120/483] Phonophobia-free at 2 hours 38.6% 30.9% .0299
[133/345] [113/366] Pain relief at 2 hours 56.0% 45.7% .0006
[304/543] [247/541] Nausea-free at 2 hours 46.9% 41.6% .1815
[149/318] [134/322] Sustained pain relief, 2-24 hours 38.9% 27.9%
.0001 [211/543] [151/541] MBS, most bothersome symptom
.sup.aEndpoints were tested hierarchically in the order shown at P
= .05 Results from Example 6 are also shown in FIG. 3.
Example 7
[0259] Efficacy of Rimegepant--Results and analysis from the
Clinical Trial--BHV3000-302 described in Example 3.
[0260] Objectives
[0261] To compare the efficacy, safety, and tolerability of
rimegepant 75 mg oral tablet with placebo in the acute treatment of
migraine in adults.
[0262] Methods
[0263] In a double-blind, randomized, placebo-controlled,
multicenter study (Study 302, NCT03237845) adults .gtoreq.18 years
of age with at least a 1-year history of ICHD 3-beta migraine were
eligible to participate. Following a 3- to 28-day screening period,
subjects were randomized to receive rimegepant 75 mg or matching
placebo and instructed to treat a single migraine attack with 1
dose of the blinded study drug (rimegepant or placebo) when
headache pain reached moderate or severe intensity. The coprimary
endpoints were pain freedom at 2 hours postdose and freedom from
the most bothersome symptom (MBS) at 2 hours postdose. Safety
assessments included adverse events (AEs), ECGs, vital signs,
physical measurements, and routine laboratory tests, including
assessment of liver function. Unless stated otherwise, values
presented are mean.+-.SD.
[0264] Results
[0265] In total, 1186 subjects were randomized to receive
rimegepant (n=594) or placebo (n=592), and 1072 were evaluated for
efficacy (rimegepant n=537, placebo n=535). Subjects had a mean age
of 40.6.+-.12.0 years, 88.7% were female, and by history had
4.6.+-.1.8 attacks per month. At 2 hours postdose, rimegepant
treated patients had higher pain free rates than placebo treated
patients (19.6% vs 12.0%, P=0.0006), were more likely to be free of
the MBS (37.6% vs 25.2%, P<0.0001); and had higher rates of pain
relief (58.1% vs 42.8%, P<0.0001). A single dose of rimegepant,
without the use of rescue medication, demonstrated superiority
versus placebo for sustained pain freedom and pain relief from 2
through 48 hours postdose (P=0.0181 and P<0.0001, respectively).
On a measure of functional disability, a greater proportion of
rimegepant-treated patients achieved normal function at 2 hours
(P<0.0001).
[0266] The safety and tolerability profiles of rimegepant were
similar to placebo. The most common AEs were nausea (1.8%, 10/543
vs 1.1%, 6/543) and urinary tract infection (1.5%, 8/543 vs 1.1%,
6/543). Serum ALT or AST levels greater than the upper limit of
normal (ULN) were seen in 2.4% (13/543) and 2.2% (12/543) of
subjects treated with rimegepant and placebo, respectively. No
subject in either treatment group had a transaminase level greater
than 3 times ULN, and no bilirubin elevations greater than 2 times
ULN were observed. Serious AEs (SAEs) were observed in 1 subject in
the rimegepant group (back pain) and 2 subjects in the placebo
group. No SAEs were determined to be related to the study drug.
[0267] Conclusions
[0268] Significant and durable clinical effects were seen with a
single dose of rimegepant across multiple outcome measures,
including pain freedom, freedom from MBS, pain relief, and recovery
of normal function. Rimegepant 75 mg oral tablet demonstrated
favorable tolerability and safety, including a liver safety profile
similar to placebo. These clinically meaningful results complement
the benefits seen in Study 301. Rimegepant may ultimately offer
patients a novel approach for the acute treatment of migraine.
TABLE-US-00013 Rimegepant Endpoints 75 mg Placebo P-value.sup.a
Coprimary Pain-free at 2 hours 19.6% 12.0% .0006 [105/537] [64/535]
Free from MBS at 2 hours 37.6% 25.2% <.0001 [202/537] [135/535]
Selected secondary Photophobia-free at 2 hours 37.4% 22.3%
<.0001 [183/489] [106/477] Phonophobia-free at 2 hours 36.7%
26.8% .0039 [133/362] [100/374] Pain relief at 2 hours 58.1% 42.8%
<.0001 [312/537] [229/535] Nausea-free at 2 hours 48.1% 43.3%
.2084 [171/355] [145/336] Sustained pain relief, 2-24 hours 42.6%
26.5% <.0001 [229/537] [142/535] MBS, most bothersome symptom
.sup.aEndpoints were tested hierarchically in the order shown at P
= .05 Results from Example 7 are also shown in FIG. 4.
Example 8
[0269] Clinical Trial--BHV3000-303: Phase 3: Double-Blind,
Randomized, Placebo-Controlled, Safety and Efficacy Trial of
BHV-3000 (Rimegepant) Orally Discintegrating Tablet (ODT) for the
Acute Treatment of Migraine (ClinicalTrials.gov Identifier:
NCT03461757)
[0270] A phase 3 clinical study was conducted with 1812
participants, as follows.
Study Description
Brief Summary:
[0271] The purpose of this study is to compare the efficacy of
BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute
Migraines.
TABLE-US-00014 Condition or disease Intervention/treatment Phase
Migraine Drug: Rimegepant Drug: Placebo Phase 3
Study Design
[0272] Study Type: Interventional (Clinical Trial) [0273] Actual
Enrollment: 1812 participants [0274] Allocation: Randomized [0275]
Intervention Model: Parallel Assignment [0276] Masking: Triple
(Participant, Care Provider, Investigator) [0277] Primary Purpose:
Treatment [0278] Official Title: BHV3000-303: Phase 3,
Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy
Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT)
for the Acute Treatment of Migraine [0279] Actual Study Start Date:
Feb. 27, 2018 [0280] Actual Primary Completion Date: Oct. 8, 2018
[0281] Actual Study Completion Date: Oct. 15, 2018
Arms and Interventions
TABLE-US-00015 [0282] Arm Intervention/treatment Experimental: Arm
1: Drug: Rimegepant BHV-3000 (Active) BHV-3000 (rimegepant) 75 mg
(ODT) Placebo Comparator: Arm 2: Drug: Placebo Placebo Comparator
Drug 75 mg matching placebo ODT
Outcome Measures
Primary Outcome Measures:
[0283] 1. Pain freedom of rimegepant compared with placebo in the
acute treatment of migraine will be measured using the number of
evaluable subjects that report no pain at 2 hours post-dose. [Time
Frame: Two hours post dose] Pain will be measured on a 4 point
Likert scale (0=none, 1=mild, 2=moderate, 3=severe) 2. Freedom from
the most bothersome symptom (MBS) of rimegepant compared with
placebo will be measured using the number of evaluable subjects
that report the absence of their MBS at 2 hours post-dose. [Time
Frame: Two hours post dose] The MBS (nausea, phonophobia or
photophobia) will measured using a binary scale (0=absent,
1=present).
Secondary Outcome Measures:
[0284] 1. To measure rimegepant compared to placebo on Pain Relief,
at 2 hours post-dose, that report a pain level of moderate or
severe at baseline and then report a pain level of none or mild.
[Time Frame: 2 hours post-dose] Pain Relief as measured by a 4
point numeric rating scale (None, Mild, Moderate, Severe) 2.
Functional disability scale [Time Frame: 2 hour post-dose] Subjects
self-report "normal" on the functional disability scale 3.
Rimegepant compared to placebo on sustained pain relief, from 2 to
24 hours by using the number of subjects that do not use any rescue
medications, and do not experience any moderate or severe headache
pain through that time. [Time Frame: 2 hours-24 hours post-dose]
Sustained Pain Relief as measured by a 4 point numeric rating scale
(None, Mild, Moderate, Severe) 4. Sustained freedom from most
bothersome symptom from 2 to 24 hours, assessed by using the number
of subjects that do not experience their most bothersome symptom
through below time period. [Time Frame: 2 to 24 hours post dose]
Most bothersome symptom 5. To measure rimegepant compared to
placebo on the probability of requiring rescue medication will be
assessed using the number of subjects that take rescue medication
within 24 after administration of study medication (BHV3000 or
placebo). [Time Frame: up to 24 hours post-dose]
Requiring Rescue Medication
[0285] 6. Sustained ability to function at a normal level as
measured by the Functional disability scale [Time Frame: 2 to 24
hours post dose] Subjects self-report "normal" on the functional
disability scale 7. Rimegepant compared to placebo on sustained
pain relief from 2 to 48 hours, using the number of subjects that
do not use any rescue medications and do not experience moderate to
severe headache pain. [Time Frame: 2 hours-48 hours post-dose]
Sustained Pain Relief as measured by a 4 point numeric rating scale
(None, Mild, Moderate, Severe) 8. Rimegepant compared to placebo on
pain freedom from most bothersome symptom from 2-48 hours post
dose. [Time Frame: 2 to 48 hours post dose] Most bothersome symptom
9. Sustained ability to function at a normal level as measured by
the Functional disability scale [Time Frame: 2 to 48 hours post
dose] Subjects self-report "normal" on the functional disability
scale 10. Rimegepant compared to placebo by tabulating the number
of subjects that report the absence of photophobia at 2 hours
post-dose in the subset of subjects that reported the presence of
photophobia at headache baseline [Time Frame: 2 hours post-dose]
Freedom from Photophobia 11. Functional disability scale [Time
Frame: 90 minutes post dose] Subjects self-report "normal" on the
functional disability scale 12. Rimegepant compared to placebo on
sustained pain relief at 90 minutes, using the number of subjects
that do not use any rescue medications and do not experience
moderate to severe headache pain. [Time Frame: 90 minutes post
dose] Pain Relief as measured by a 4 point numeric rating scale
(None, Mild, Moderate, Severe) 13. Rimegepant compared to placebo
from 2 to 24 hours, using the number of subjects that do not
experience any headache pain through the time period of interest.
[Time Frame: 2 hours-24 hours post-dose] Sustained Pain Freedom as
measured by a 4 point numeric rating scale (None, Mild, Moderate,
Severe) 14. Sustained freedom from most bothersome symptom at 90
minutes, assessed by using the number of subjects that do not
experience their most bothersome symptom through below time period.
[Time Frame: 90 minutes post-dose] Most bothersome symptom 15.
Rimegepant compared to placebo on sustained pain freedom 90 minutes
post dose, will be measured using the number of subjects that do
not experience any headache pain through the time period of
interest. [Time Frame: 90 minutes post-dose] Sustained Pain Freedom
as measured by a 4 point numeric rating scale 16. Rimegepant
compared to placebo by tabulating the number of subjects that
report the absence of phonophobia at 2 hours post-dose in the
subset of subjects that reported the presence of phonophobia at
headache baseline [Time Frame: 2 hours post-dose] Freedom from
Phonophobia 17. Rimegepant compared to placebo on sustained pain
freedom, from 2 to 48 hours, will be measured using the number of
subjects that do not experience any headache pain through the time
period of interest. [Time Frame: 2 hours-48 hours post-dose]
Sustained Pain Freedom as measured by a 4 point numeric rating
scale (None, Mild, Moderate, Severe) 18. To measure rimegepant
compared to placebo on Pain Relief, at 60 minutes post-dose, that
report a pain level of moderate or severe at baseline and then
report a pain level of none or mild. [Time Frame: 60 minutes post
dose] Sustained Pain Relief as measured by a 4 point numeric rating
scale (None, Mild, Moderate, Severe) 19. Functional disability
scale [Time Frame: 60 minutes post dose] Subjects self-report
"normal" on the functional disability scale 20. Freedom from Nausea
will by tabulating the number of subjects that report the absence
of nausea at 2 hours post-dose in the subset of subjects that
reported the presence of nausea at headache baseline. [Time Frame:
2 hours post-dose] Freedom from Nausea 21. To assess the number of
subjects that are pain free at 2 hours post-dose and then have a
headache of any severity (response of 1, 2 or 3 on the 4-point
scale within 48 hours after administrations of study medication,
rimegepant or placebo. [Time Frame: 2 hours-48 hours post-dose]
Pain relapse
[0286] Further details concerning the clinical study including
eligibility criteria, contacts and locations and more information
can be found at www.clinicaltrials.gov for ClinicalTrials.gov
Identifier: NCT03461757.
Example 9
[0287] Results from the clinical trial described in Example 8 are
summarized as follows.
[0288] Study 303 met its co-primary registrational endpoints of
pain freedom and freedom from most bothersome symptom (MBS) at 2
hours using a single dose (Table 8). Importantly, patients treated
with the rimegepant Zydis ODT formulation in accordance with the
present invention began to numerically separate from placebo on
pain relief as early as 15 minutes and demonstrated statistical
significance by 60 minutes (p<0.0001) (see FIG. 5). FIG. 5 shows
the percentage of patients experiencing pain relief between 0 and 2
hours after dosing for patients who took a single dose of
rimegepant Zydis ODT 75 mg or placebo. Data are Kaplan-Meier
exploratory estimates with pain relief defined as patients who have
either mild-pain or no-pain during the specified interval. Subjects
were censored who took rescue medication or were lost to follow-up
during the specified interval. Additionally, a significantly
greater percentage of patients treated with rimegepant Zydis ODT
returned to normal functioning within 60 minutes as compared to
placebo (p<0.002). Lasting clinical benefit was observed through
48 hours on pain relief (p<0.001), pain freedom (p<0.001),
most bothersome symptom (p<0.001), functional disability
(p<0.003) and multiple other secondary endpoints after a single
dose of rimegepant as compared to placebo. The vast majority of
patients treated with rimegepant Zydis ODT (85%) did not use any
rescue medications.
TABLE-US-00016 TABLE 8 Study 303 Pain Freedom & Freedom from
Most Bothersome Symptom Rimegepant Placebo Adjusted 2 Hour Endpoint
(N = 669) (N = 682) Difference p-value Pain Freedom 21.2% 10.9%
10.3% <0.0001 Freedom from MBS.sup.1 35.1% 26.8% 8.3% 0.0009
[0289] In Study 303, rimegepant Zydis ODT statistically
differentiated from placebo on the two co-primary endpoints as well
as the first 21 consecutive secondary outcome measures were
prespecified in hierarchical testing (p-values <0.05). These
secondary outcomes and additional exploratory outcome measures from
this study are anticipated to be presented at upcoming scientific
meetings in 2019.
[0290] The safety and tolerability of rimegepant in Study 303 was
consistent with the profile previously observed in Study 301
(Example 2) and 302 (Example 3). Table 9 shows the pooled safety
data across all three trials. No single adverse event (AE) occurred
in the rimegepant group with an incidence higher than 1.6% and
overall rates of AEs were similar to placebo. With regard to liver
function tests, one patient treated with placebo and one patient
treated with rimegepant showed LFTs>3.times.ULN in Study 303.
Pooled liver function test results across the three pivotal trials
(n=3,556) performed to date showed that rimegepant was similar to
placebo with regard to aminotransferase (ALT or AST) levels above
the upper limit of normal (ULN) and no patients experienced
elevations in bilirubin >2.times.ULN (Table 10).
TABLE-US-00017 TABLE 9 Pooled Adverse Event (AE) Safety Data:
Complete Dataset of AEs from Studies 301, 302 and 303 of Patients
Reporting an AE within 48 Hours Post-Dose .gtoreq.1% Incidence
Rimegepant Placebo Adverse Event (n = 1,771) (n = 1,785) .gtoreq.1
On-Study AE* 252 (14.2%) 209 (13.2%) Nausea 26 (1.5%) 15 (0.8%) UTI
21 (1.2%) 12 (0.7%) SAEs** 3 (0.2%) 3 (0.2%) *No other individual
AEs .gtoreq.1%, in rimegepant treated subjects, than listed in
table. Includes all AEs without attribution to drug relatedness.
**No drug-related Serious Adverse Events (SAEs). 2 of the subjects
with SAE in rimegepant group and 1 in placebo group had not been
dosed before onset of SAE.
TABLE-US-00018 TABLE 10 Pooled Liver Function Test (LFT) Profile:
Complete Dataset of LFT Results from Studies 301, 302, and 303*
Rimegepant Placebo ALT or AST (n = 1,771) (n = 1 ,785)
>ULN.sup.1 48 (2.7%) 52 (2.9%) >3.times. ULN 2 (0.1%) 2
(0.1%) >5.times. ULN 1 (0.06%) .sup.2 0 >10.times. ULN 0 0
>20.times. ULN 0 0 .sup.1Upper limit of normal; ALT alanine
aminotransferase; AST aspartate aminotransferase .sup.2 AST
elevation, Not Drug-Related as deemed by the investigator: subject
newly initiated weight-lifting with laboratory results consistent
with muscle injury *AST/ALT Categories are not mutually exclusive;
No bilirubin elevations >2.times. ULN across Studies 301, 302
and 303
[0291] Further results from the clinical trial described in Example
8 (Study 303) are shown in Tables 11, 12 and FIG. 6.
TABLE-US-00019 TABLE 11 ORDER Primary Endpoints Rimegepant Placebo
P-value Primary, 1 Pain @ 2 hrs 21.2% 10.9% <0.0001 Primary, 2
MBS @ 2 hrs 35.1% 26.8% 0.0009 SECONDARY ORDER Secondary Endpoints
BHV PBO P-value 1 Pain Relief @ 2 hours 59.3% 43.3% <0.0001 2
Functional Disability at 2 hours 38.1% 25.8% <0.0001 3 SP Relief
2 to 24 hours 47.8% 27.7% <0.0001 4 MBS 2 to 24 27.1% 17.7%
<0.0001 5 Prob of Rescue Meds in 24 14.2% 29.2% <0.0001 hours
6 Functional Disability 2 to 24 29.6% 16.9% <0.0001 7 SP Relief
2 to 48 hours 42.2% 25.2% <0.0001 8 MBS 2 to 48 23.2% 16.4%
0.0018 9 Functional Disability 2 to 48 26.0% 15.4% <0.0001 10
Photophobia @2 hours 33.4% 24.5% 0.0007 11 Functional Disability @
90 30.2% 21.3% 0.0002 minutes 12 Pain Relief @ 90 minutes 49.6%
37.2% <0.0001 13 SP Freedom 2 to 24 hours 15.7% 5.6% <0.0001
14 MBS Freedom at 90 minutes 27.4% 21.5% 0.0128 15 Pain Freedom @
90 minutes 15.1% 7.3% <0.0001 16 Phonophobia @ 2 hours 41.7%
30.2% 0.0003 17 SP Freedom 2 to 48 hours 13.5% 5.4% <0.0001 18
Pain Relief at 60 minutes 36.8% 31.2% 0.0314 19 Functional
Disability at 60 22.3% 15.8% 0.0025 minutes 20 Nausea @ 2 hours
51.0% 45.2% 0.0898 21 Pain Relapse 2 to 48 36.6% 50.0% 0.0577
TABLE-US-00020 TABLE 12 RIMEGEPANT (BHV-3000) PHASE 3-STUDY 303
Sustained Pain Relief.sup.1 from 2, 3, & 4 to 24 or 48 hours
Sustained Pain Rimegebant Placebo Relief n = 669 n = 682 p-value 24
hr 2 to 24 hrs 47.8% 27.7% <0.0001 3 to 24 hrs 56.4% 33.1%
<0.0001 4 to 24 hrs 61.7% 36.8% <0.0001 48 hr 2 to 48 hrs
42.2% 25.2% <0.0001 3 to 48 hrs 49.9% 29.8% <0.0001 4 to 48
hrs 54.7% 33.0% <0.0001 .sup.1Sustained Pain Relief is defined
as patients who have either mild-pain or no-pain pain during the
specified interval, with no use of rescue medication. Analyses of
3-24, 4-24, and 4-48 hours are exploratory.
Example 10
Clinical Trial--BHV3000-201: Open Label Safety Study in Acute
Treatment of Migraine (ClinicalTrials.gov Identifier: NCT
03266588)
[0292] A phase 2/3 clinical study is conducted with about 2000
participants, as follows.
Study Description
Brief Summary:
[0293] The purpose of this study is to evaluate safety and
tolerability of BHV3000 (rimegepant).
TABLE-US-00021 Condition or disease Intervention/treatment Phase
Migraine Drug: Rimegepant Phase 2 Phase 3
Study Design
[0294] Study Type: Interventional (Clinical Trial) [0295] Estimated
Enrollment: 2000 participants [0296] Intervention Model: Single
Group Assignment [0297] Masking: None (Open Label) [0298] Primary
Purpose: Treatment [0299] Official Title: A Multicenter, Open Label
Long-Term Safety Study of BHV3000 in the Acute Treatment of
Migraine [0300] Actual Study Start Date: Aug. 30, 2017 [0301]
Estimated Primary Completion Date: July 2019 [0302] Estimated Study
Completion Date: July 2019
Arms and Interventions
TABLE-US-00022 [0303] Arm Intervention/treatment Experimental:
Rimegepant Drug: Rimegepant 75 mg oral tablet Other Name:
BHV3000
Outcome Measures
Primary Outcome Measures:
[0304] 1. To assess the safety and tolerability of rimegepant
(BHV-3000) by measuring the frequency and severity of adverse
events and discontinuations due to adverse events [Time Frame: 52
weeks] Number of subjects with treatment-emergent adverse events as
assessed through laboratory tests, ECGs, physical exam findings
(safety and tolerability)
Secondary Outcome Measures:
[0305] 1. ALT or AST>3.times.ULN with total bilirubin
>2.times.ULN [Time Frame: 52 weeks] elevated liver function
tests 2. hepatic related adverse events and hepatic related adverse
events that lead to discontinuation [Time Frame: 52 weeks] adverse
events related to liver
[0306] Further details concerning the clinical study including
eligibility criteria, contacts and locations and more information
can be found at www.clinicaltrials.gov for ClinicalTrials.gov
Identifier: NCT03266588.
Example 11
[0307] Results from the clinical trial described in Example 10 are
summarized as follows. Study BHV3000-201 demonstrated initial
positive results. The interim analysis (database cutoff of Nov. 21,
2018) demonstrated that the safety and tolerability of long-term
dosing of rimegepant in patients with migraine is consistent with
the profile observed in phase 1-3 studies to date. Patients were
allowed to treat migraine attacks of all severities (mild to
severe) up to once daily for a full year. The initial results for
hepatic safety and tolerability of rimegepant 75 mg in study
participants is based upon review of both adverse events and
regularly scheduled liver function tests. Interim hepatic data were
reviewed by an external and independent panel of liver experts.
There were no liver cases assessed as probably related to study
drug and there were no Hy's Law cases identified. The panel
concluded that there was no liver safety signal detected to date,
including a subset of patients with near-daily dosing (Z 15
doses/month). In the aggregate, it was noted that compared to
migraine trials with drugs other than rimegepant, there was a very
low incidence of overall elevations of liver function test
abnormalities in rimegepant treated patients (1.0% incidence of
serum ALT or AST>3.times.ULN). Subjects will continue to
participate in Study 201 with additional data analyses to be
submitted in the NDA and required 120-day safety updates.
[0308] In addition to the interim safety analysis, data from
subjects was assessed to determine reductions in the number of
headache days per month. The data presented in Table demonstrate
that patients experienced fewer headache days per month while
taking rimegepant during their treatment phase versus their
observation phase of the study. For example, of 1731 subjects, 683
(39.5%) had a reduction in headache days per month of at least 20%,
602 (34.8%) had a reduction in headache days per month of at least
25%, 523 (30.2%) had a reduction in headache days per month of at
least 30%, 442 (25.5%) had a reduction in headache days per month
of at least 35%, 362 (20.9%) had a reduction in headache days per
month of at least 40%, 287 (16.6%) had a reduction in headache days
per month of at least 45%, 226 (13.1%) had a reduction in headache
days per month of at least 50%. This result was surprising and
unexpected and indicates that rimegepant may function as a
preventative treatment for migraine as well as an acute treatment.
Reductions in the mean number of headache days per month was
observed beginning as early as the first month and continued in
subsequent months of therapy.
[0309] Accordingly, in accordance with the present invention, it
may be possible to treat patients that suffer from migraine
headaches by administering rimegepant to the patient at a dosage,
e.g., 75 mg, and at a frequency, e.g., once per month, twice per
month, three times per month, four times per month, five or more
times per month, ten or more times per month, fifteen or more times
per month, effective to reduce the number of headaches per month,
e.g., a 20% or greater reduction in the number.
TABLE-US-00023 TABLE 13 BHV-3000-201-Percent Decrease in Migraines
per Month Enrollment Enrollment Enrollment Group Group Group (2-8)
(9-14) (4-14) Overall Overall Percent Decrease n 1004 458 269 1731
>= 20.0% decrease 353 (35.2) 171 (37.3) 159 (59.1) 683 (39.5)
>= 25.0% decrease 308 (30.7) 150 (32.8) 144 (53.5) 602 (34.8)
>= 30.0% decrease 268 (26.7) 125 (27.3) 130 (48.3) 523 (30.2)
>= 35.0% decrease 224 (22.3) 101 (22.1) 117 (43.5) 442 (25.5)
>= 40.0% decrease 181 (18.0) 81 (17.7) 100 (37.2) 362 (20.9)
>= 45.0% decrease 144 (14.3) 60 (13.1) 83 (30.9) 287 (16.6)
>= 50.0% decrease 113 (11.3) 46 (10.0) 67 (24.9) 226 (13.1)
[0310] Throughout this application, various publications are
referenced by author name and date, or by patent number or patent
publication number. The disclosures of these publications are
hereby incorporated in their entireties by reference into this
application in order to more fully describe the state of the art as
known to those skilled therein as of the date of the invention
described and claimed herein. However, the citation of a reference
herein should not be construed as an acknowledgement that such
reference is prior art to the present invention.
[0311] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, numerous
equivalents to the specific procedures described herein. Such
equivalents are considered to be within the scope of this invention
and are covered by the following claims. For example,
pharmaceutically acceptable salts other than those specifically
disclosed in the description and Examples herein can be employed.
Furthermore, it is intended that specific items within lists of
items, or subset groups of items within larger groups of items, can
be combined with other specific items, subset groups of items or
larger groups of items whether or not there is a specific
disclosure herein identifying such a combination.
* * * * *
References